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ABSTRACT OF DISSERTATION

INVESTIGATING THE ROLE OF PRESCRIPTION DRUG MONITORING PROGRAMS IN
REDUCING RATES OF OPIOID-RELATED POISONINGS
The United States is in the midst of an opioid epidemic. In addition to other system level
interventions, almost all states have responded to the crisis by implementing
prescription drug monitoring programs (PDMPs). PDMPs are state-level interventions
that track the dispensing of Controlled Substances. Data generated at the time of
medication dispensing is uploaded to a central data server that may be used to assist in
identifying drug diversion, medication misuse, or potentially aberrant prescribing
practices.
Prior studies assessing the impact of PDMPs on trends in opioid-related morbidity have
often failed to take into account the wide heterogeneity of program features and how
the effectiveness of these features may be mitigated by insurance status. Previous
research has also failed to differentiate the effects of these programs on prescription vs.
illicit opioid-related morbidity. The studies in this dissertation attempt to address these
gaps using epidemiological techniques to examine the associations between specific
PDMP features and trends in prescription and illicit opioid-related poisonings in
populations of different insurance beneficiaries.
Results of these studies demonstrate that implementation of specific PDMP features is
significantly associated with differential trends in prescription and illicit-opioid related
poisonings and that the effectiveness of these features vary depending on the insurance
status of the population studied. These results suggest that PDMPs offer a valuable tool
in addressing the United States’ opioid epidemic, and may be used as empirical evidence
to support PDMP best practices in the future.
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Introduction
In February 2011, the US Centers for Disease Control and Prevention (CDC)
labelled recent increases in opioid-related morbidity and mortality as ‘a US epidemic’.1
Opioid-related poisonings recently surpassed automobile accidents as the leading cause
of accidental injury death in the US.2 In 2016, over 42,000 individuals died from an
opioid-related poisoning—about 115 deaths per day—and in October 2017, President
Trump declared the crisis a national public health emergency.3,4 This burgeoning
epidemic has afflicted Americans from all walks of life including the young, poor, rich,
and old, and has united activists, politicians, and scientists in an attempt to stymie the
overwhelming increase in preventable mortality.
The opioid epidemic has roots as an iatrogenic crisis. In the late 1990’s a host of
factors converged to result in rapid increases in the prescribing of opioid analgesics. The
patient-centered health movement combined with a growing recognition of pain as a
legitimate clinical condition led to a push to treat pain throughout the healthcare sector.
At the same time, the potent opioid analgesic OxyContin® was aggressively marketed to
physicians as an efficacious and non-addictive method of pharmacological pain
management.5-8 From 1999 to 2010, opioid analgesic prescriptions in the US increased
approximately 4-fold along with a concurrent increase in opioid-related morbidity and
mortality.9-11
In recent years, a variety of state and federal-level interventions have been
deployed in an effort to encourage more responsible opioid prescribing practices.
Interventions include crackdowns on ‘pill mills’ in certain states, the development of
1

abuse deterrent formulations, and the revision of prescribing guidelines. 12-19 Policy
makers have also responded to the ongoing crisis by establishing prescription drug
monitoring (PDMPs). PDMPs are state-based programs that the track the prescribing
and dispensing of controlled substances to consumers with a goal of mitigating misuse
and diversion.20 PDMP data may assist prescribers and pharmacists in their decisionmaking at the point of care and may also assist law enforcement and licensure boards in
the identification of potentially aberrant prescribing and dispensing practices. Ideally,
PDMPs offer the opportunity for providers to adequately manage pain with opioid
analgesics while also preventing opioid misuse and opioid-related morbidity and
mortality.
At present, 49 states and the District of Columbia have operational PDMPs.21
Given the widespread implementation of these programs, numerous studies have
sought to examine associations between PDMPs and trends in opioid-related morbidity
and mortality. This previous research has found generally inconsistent evidence of
PDMP efficacy.22 There are a number of prominent shortcomings in the current body of
PDMP research. Many studies have to adequately account for program heterogeneity
between states. Also, no studies to date have explored the differential effects of these
programs on trends in prescription and illicit opioid-related morbidity and mortality, or
whether insurance status effects program efficacy. The research presented in this
dissertation makes use of robust epidemiological methods and multiple data sources to
address these gaps in the PDMP literature.

2

Chapter 1 contains a literature review that explores the history of PDMPs as a
response to the opioid epidemic, and summarizes previous work examining associations
between PDMPs and trends in opioid related-morbidity and mortality. Chapter 2
consists of two separate, but related, analyses that asses associations between specific
PDMP features and trends in prescription and illicit opioid-related poisonings in a
nationally representative sample of privately insured adults. Chapter 3 presents an
examination of differential associations between PDMP features and trends in
prescription opioid-related poisonings in populations with different types of insurance
coverage. Finally, Chapter 4 compares the results of the previous two chapters and
explores policy recommendations and future research on this topic. Taken together,
these studies make a novel contribution to the existing PDMP literature that will
ultimately be useful to both researchers and policy makers seeking to quell the opioid
epidemic.
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Chapter 1: A Brief History of Prescription Drug Monitoring Programs and Their
Associations with Opioid-Related Morbidity and Mortality
1.1 Introduction: Prescription Drug Monitoring Programs as a Response to the Opioid
Epidemic
In 1998, the Veterans Health Administration (VHA) began developing a clinical
strategy to improve pain management for its beneficiaries.23 The next year, the VHA
rolled out an initiative called “Pain as the 5th Vital Sign” that mandated the assessment
and documentation of self-reported pain at every clinical encounter.24 This initiative
placed pain on par with blood pressure, respiratory rate, heart rate, and temperature,
and encouraged VHA physicians to treat pain as a condition in and of itself. In 2001, the
Joint Commission on Accreditation of Healthcare Organizations (JCAHO) released new
Pain Management Standards which continued to suggest that chronic pain is an
undertreated problem in American healthcare.25,26 Though the JCAHO did not explicitly
endorse the “Pain as the 5th Vital Sign” initiative, this report may have helped popularize
the concept.27
Interest in pain as a potentially undertreated condition has persisted throughout
the 21st century. The National Center for Health Statistics (NCHS) releases an annual
report regarding the current state of health in the US, and their 2006 report included a
special feature on pain.28 Also in 2006, the Centers for Medicare and Medicaid Services
implemented the Hospital Consumer Assessment of Healthcare Providers and Systems
survey, which requires hospitals to ask discharged patients subjective questions
regarding pain management, amongst other things.29 More recently, the 2010 Patient
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Protection and Affordable Care Act mandated that the Department of Health and
Human Services enlist the Institute of Medicine (IOM), “to increase the recognition of
pain as a significant public health problem in the United States.”30 In keeping with this
requirement, the IOM conducted a study in 2011 to assess the current state of science
regarding pain research, care, and education. Results of the IOM study revealed that
more than 116 million adults living in the US experience chronic pain conditions.30 Pain
also exerts a significant financial burden on US society, costing at least $560-$625 billion
annually, and in 2008, the estimated direct cost to federal and state governments for
medical expenditures related to pain was approximately $99 billion. 30
Prescription opioid analgesics have demonstrated short-term effectiveness in
relieving many types of moderate to severe pain.30-34 Use of opioid analgesics has
increased markedly since the late 90’s, owing, in part, to increasing awareness and
efforts to address untreated pain.9,30,35-38 From 1999 to 2010, opioid prescriptions in the
US increased approximately 4-fold.9 In 2012, 259 million prescriptions were written for
opioid analgesics—more than one for every US adult.39 Furthermore, it has been
estimated that Americans presently consume approximately 80% of the global supply of
prescription opioids and 99% of the global supply of hydrocodone, despite comprising
less than 5% of the world’s population.38 The explosion in opioid analgesic use in the US
has surely benefitted some patients suffering from chronic pain; however, it has also
been associated with a number of serious negative ramifications.
The increasing use of opioid analgesics has been paralleled by increasing rates of
nonmedical use, use disorders, and diversion of these medications.38,40-43 In 2014, more
5

than 10 million Americans reported using opioids non-medically, and 1.9 million
Americans met the criteria for an opioid use disorder based on their past-year use of
prescription opioids.44 A 2015 study by Dart et al. assessed changes in the rate of opioid
misuse using three different datasets managed by the Researched Abuse, Diversion, and
Addiction-Related Surveillance (RADARS) System.40 Results were consistent across all
three datasets and revealed that rates of opioid misuse and opioid-related poisonings all
nearly doubled from 2002 to 2013.40 Persons with nonmedical prescription opioid
analgesic use and/or opioid use disorders often obtain medications from multiple
providers, a behavior known as “doctor shopping”, or from friends, relatives, or
strangers who are prescribed the medication for legitimate medical reasons, a practice
known as “diversion”. Importantly, most illicit drugs in the US are from foreign
countries, while most misused prescription opioids originate from US prescribers.45 Dart
et al. also used the RADARS data to examine changes in opioid diversion and found that
the rate of opioid diversion increased by nearly 67% from 2002 to 2013.40
In addition to increasing rates of nonmedical use, opioid use disorders, and
diversion, increasing use of opioid analgesics since the late 1990’s has also been
associated with a corresponding increase in opioid analgesic related mortality. One of
the first studies to identify this trend found that the number of opioid analgesic
poisonings listed on death certificates increased 91.2% from 1999 – 2002, and by 2002,
opioid analgesics resulted in more poisoning deaths than heroin and cocaine
combined.10 A 2009 study found that the number of fatal poisonings involving opioid
analgesics more than tripled from 1999 to 2006 and also found that the percentage of
6

poisonings involving opioid analgesics increased steadily over the same time period. 46
The number of fatal poisonings involving opioids increased nearly 8% from 2006 to 2008
and in 2008, it was observed that opioid analgesics were involved in 73.8% of all
prescription drug overdose deaths.46,47 More recently, a 2014 study found that the rate
of opioid related poisonings (prescription opioids and heroin) increased 200% from 2000
to 2014 and in 2014 the number of fatal opioid related poisonings was nearly equal to
the number of deaths from motor vehicle accidents. 11 Rates continued to increase
across the United States from 2014 to 2015 in all demographic subgroups assessed. 2
The American healthcare system thus finds itself at the nexus of two
interconnected and seemingly paradoxical public health epidemics. One being the
chronic under-treatment of pain, or the ineffective treatment of underlying causes of
pain, and the other being morbidity and mortality stemming from opioid analgesic
medications used to treat that pain. Recognizing this conundrum, the Executive Office of
the President released a plan in 2011 to address these intertwined problems and set
forth a call to, “take urgent action to ensure the appropriate balance between the
benefits these medications [opioid analgesics] offer… and the risks they pose.” 48 The
President’s call may represent a delayed recognition of the problem. In the years leading
up to the release of this plan, many states had already attempted to strike such a
balance through the adoption of Prescription Drug Monitoring Programs (PDMPs).
PDMPs are state-based programs that track the prescribing and dispensing of
Controlled Substances (CS) to consumers. Information on a consumers’ CS use history
may be made available to prescribers, dispensers, or law enforcement agents
7

authorized to query the PDMP data. These data may assist providers in making
prescribing decisions and may also assist in the identification of individuals engaged in
doctor shopping or medication diversion. Ideally, the hope was that PDMPs would offer
the opportunity to adequately treat pain with opioid analgesics while also stymieing
doctor shopping and diversion—two of the primary drivers of prescription opioid
related morbidity and mortality. At present, 49 states and the District of Columbia have
operational PDMPs.49 Over the last 15 years, many studies have sought to examine the
impact of PDMPs on prescription opioid-related morbidity and mortality, yet the
findings of these studies are at times inconsistent. This review seeks to summarize
academic literature pertaining to the history, evolution, and impact of PDMPs on opioid
related morbidity and mortality in the United States. The specific aims of this review are
to:
1. Describe the history and evolution of PDMPs
2. Examine associations between PDMPs and opioid-related morbidity (e.g.
nonfatal poisonings, treatment admissions, etc.)
3. Assess associations between PDMPs and opioid-related mortality
4. Describe gaps in the existing PDMP literature
1.2 Methods
The search engines PubMed and Google Scholar were used to search for
combinations of the following keywords and phrases: prescription drug monitoring
program, PDMP, PMP, opioid, heroin, poisoning, treatment, mortality, and morbidity.
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Literature was excluded if the topic lay outside the specific aims listed above, was
published in a language other than English, or was published as a ‘letter to the editor’ or
opinion piece. In terms of evaluating aims 2 and 3 above, only studies where the
outcome of interest was specifically related to prescription or illicit opioid-related
morbidity or mortality were included the review.
1.3 Results
1.3.1 History and Evolution of PDMPs
Interest in tracking the prescribing of addictive goods has existed in the United
States since the early 1900s.50 In 1914, New York State passed The Boylan Act, which
required physicians to use state-issued, serial-numbered, prescription order blanks
when prescribing certain narcotics.51 The Act mandated that patients be given a copy of
their prescription order while physicians were required to keep a duplicate copy on file
for five years to be available for inspection by state authorities at any time. 51 This was
the first Multiple Copy Prescription Program (MCPP) in the United States and
symbolized the regulatory/public policy desire to be able to track prescriptions over
time – essentially foreshadowing the advent of future PDMPs. California and Hawaii
soon followed New York’s suite and instituted their own MCPPs in 1939 and 1943,
respectively.50 Although all three of the early MCPPs operated similarly, the drugs they
chose to monitor varied greatly and formal requirements dictating use of the programs
differed in each state.50

9

The Controlled Substances Act of 1970 established federal policy that regulates
the manufacture, possession, and use of certain substances.52 This legislation created
five federally designated ‘Schedules’ that classify substances based on their abuse
potential and medical utility. The Food and Drug Administration (FDA) and the Drug
Enforcement Agency (DEA) jointly determine which substances are added to or removed
from the five various schedules. Notably, individual states can reschedule a medication
to a more restrictive schedule or make a federally unscheduled drug a scheduled drug in
that particular state. While only illicit substances with no recognized medical utility are
included in Schedule I, prescription medications may be found in Schedule II—drugs
with an accepted medical use but with a high potential for abuse or physical
dependence—to Schedule V—drugs with accepted medical use but with very low
potential for abuse or physical dependence.
Thus, the Controlled Substances Act offered guidance to states seeking to
monitor the prescribing of potentially dangerous medications and implicitly encouraged
other states to join in the effort. Sure enough, the early adopters of MCPPs amended
their programs in the wake of the Controlled Substances Act to specifically monitor
Schedule II prescription medications. 50 Several other states soon began efforts to
implement their own monitoring programs, and by 1998, ten states had functioning
PDMPs.53 Only seven years later, the number of states with functioning PDMPs had
more than doubled to 25.54 Over this same time period, states began moving away from
traditional MCPPs and instead began implementing more advanced, computer based
Electronic Data Transmission (EDT) systems.50,55 EDTs were quickly seen to be more
10

user-friendly and efficacious than MCPPs, and by 2006, the last MCPP had been phased
out and all states with active PDMPs utilized EDT systems.50,56 Now, 49 states and the
District of Columbia have operational electronic PDMPs.49
Modern PDMPs serve a variety of both individual and system level purposes.
Perhaps most importantly, by tracking CS prescribing, PDMPs may assist physicians and
pharmacists in identifying patients who may be doctor or pharmacy shopping for the
purposes of diverting or misusing prescription opioids.50,57-60 A recent review of laws
that articulate the purpose of PDMPs found that most PDMP legislation cites the goals
of reducing abuse, misuse, and diversion as the primary goals of the PDMP.20 This
review found that only five PDMPs specifically list improving public health as a goal, and
none specifically listed preventing opioid-related poisonings as goals.20 Misuse,
diversion, and doctor shopping for prescription opioids are all risk factors for opioidrelated poisonings.61-64 If PDMPs are successful in reducing misuse, diversion, and
doctor shopping then they may also help mitigate population-level risk of opioid-related
poisonings. PDMPs may also be useful to law enforcement entities and boards of
licensure who can use the programs to identify providers that are prescribing
abnormally large quantities of CS.
In general, all PDMPs operate similarly. Prescription data is captured at the time
of CS dispensing and these data are periodically uploaded to a central database, which is
accessible upon query to a variety of authorized users. PDMPs may, or may not, allow
data access to prescribers, dispensers, regulatory agencies, and law enforcement
officials conducting active investigations into potentially illicit or aberrant prescribing.
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States also choose specifically which Schedules are required to be reported to the
PDMP. Currently all states monitor Schedule II medications, but there is some variability
in terms of monitoring Schedules III-V.65 Variability also exists in terms of which state
agency oversees operation of the PDMP.49 There is also wide heterogeneity in terms of
state laws requiring practitioners to register with the PDMP or mandating that they
query the central database in certain situations, with more states implementing these
requirements in recent years.53 An increasingly popular feature of PDMPs is to send
unsolicited reports to prescribers, law enforcement agencies, or regulatory bodies.53
Prescribers may receive unsolicited reports if their patients are visiting multiple
prescribers, and licensure bodies may receive unsolicited reports if providers are
observed prescribing abnormal quantities of CS. Most PDMPs have experienced major
changes to key program features throughout their lifetimes.54,65 The Prescription Drug
Abuse Policy System (PDAPS) publishes data on historical changes to PDMPs over time,
as well as interactive maps to visualize the status of current PDMPs. 66 Figures 1.1, and
1.2 are two of these maps that visualize PDMPs with requirements for unsolicited
reporting and mandatory querying, respectively.
Specific features of PDMPs may have important impacts on the programs’
efficacy in terms of reducing non-medical prescription opioid use and/or mortality. For
example, PDMPs that operate proactively by sending unsolicited reports to prescribers
or law enforcement may have a greater impact on opioid prescribing relative to states
with strictly reactive PDMPs.67 Additionally, states with PDMPs that monitor more CS
and require pharmacies to report data to the PDMP more frequently, may have a more
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significant impact on prescription drug misuse and mortality than states with less
comprehensive programs.54 Finally, requiring prescribers or dispensers to register with
and query the PDMP data in certain circumstances can have major impacts on program
efficacy.42,68 One 2015 study of Kentucky’s PDMP found that requiring prescribers to
register and utilize the program in certain situations reduced doctor shopping by over
50% compared to the year prior to the requirement going into effect. 68
Considering the past and present heterogeneity in terms of PDMP operation,
there have been several efforts to identify and promote PDMP best practices. Partially
in response to increasing opioid related morbidity and mortality and the subsequent
popularization of PDMPs, the Bureau of Justice Assistance (BJA) created the Harold
Rogers Prescription Drug Monitoring Program (HRPDMP) in 2002. 53,55 This program
made grant funding available to certain states to assist in the planning, implementation,
and enhancement of PDMPs, and charged the National Association for Model State Drug
Laws (NAMSDL) to assist in the process.53,55 In 2004, NAMSDL released a list of 7 key
characteristics of strong PDMPs and highlighted the importance of monitoring all
Schedules of CS, sending proactive reports to various entities, providing training to
providers, and allowing data access to dispensers, prescribers, law enforcement
agencies and licensing officials.69 The next year, Congress authorized additional federal
funding for PDMPs with the passage of the National All Schedules Prescription Electronic
Reporting Act (NASPER). In 2009 and 2010, nearly $10 million was appropriated by
Congress for the HRPDMP and NASPER.53 With assistance from the Alliance of States
with PDMPs, the BJA funded the PDMP Technical Training and Assistance Center (PDMP
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TTAC) at Brandeis University in 2008, and charged this group with conducting research
to enhance the effectiveness of PDMPs.55 In 2012, PDMP TTAC released a
comprehensive assessment of the evidence for PDMP best practices and determined
that more systematic research and evaluation is required to establish the value of
certain PDMP features.55
1.3.2 Associations between PDMPs and opioid-related morbidity
Since PDMPs became widely implemented in the early 2000’s, a number of
researchers have attempted to quantify the impact of the programs on measures of
prescription opioid misuse and mortality. Before delving into this literature, it is
important to clarify the language used to describe prescription opioid misuse. The
International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM)
has specific codes for both prescription opioid abuse and prescription opioid
dependence.70 These codes are defined based on criteria found in the Diagnostic and
Statistical Manual, 4th edition, text revision (DSM-IV), which also differentiates between
substance abuse disorders and dependence.71 In the more recent Diagnostic and
Statistical Manual, 5th edition (DSM-V), though, these categories have been collapsed
into a single umbrella diagnosis of substance use disorder, which is further categorized
by severity.72 These changes reflect a trend in the medical community moving away
from describing substance use as an abusive behavior to more accurately reflect the
underlying neurobiological condition contributing to substance misuse or dependence. 73
Referring to individuals with substance use disorders as ‘drug abusers’ stigmatizes these
individuals and fails to properly convey the subtleties of their disorder. 73 In October
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2016, the Office of National Drug Control Policy released draft guidelines for federal
agencies to use appropriate language when referring to addiction, dependence, and
substance use disorders.74 Some of the literature discussed in this section uses the
misappropriated language of ‘opioid abuse’ to refer to various measures of opioid
misuse. In reality, opioid abuse is only accurate terminology when referring to the
specific DSM-IV diagnosis. Thus, for the purposes of this paper, authors’ definitions of
opioid abuse will be explained, but the term opioid misuse will be used to refer to the
results of their studies.
Commonly Used Data Sources
One of the most popular datasets for studying trends in prescription opioid
misuse is the Treatment Episode Data Set (TEDS). The TEDS system is maintained by the
Substance Abuse and Mental Health Services Administration (SAMHSA) and includes
data on 1.5 million substance abuse treatment admissions annually. TEDS includes data
collected at the state level on admissions to state or federally funded substance abuse
treatment facilities.75 Importantly, TEDS captures information on primary substance of
misuse (defined as the substance bringing the patient into treatment) as well as other
patient characteristics at the time of treatment admission.75 A notable limitation of the
TEDS data is that it only captures admissions to publicly funded treatment facilities, and
in doing so only offers a snapshot of the overall burden of opioid misuse in the US. An
additional limitation is that patients presenting for treatment and included in the TEDS
data may or may not actually have a DSM-4 diagnosis of ‘opioid abuse’. Thus, while
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many researchers use TEDS data to study trends in ‘opioid abuse’, they are in fact
assessing a measure of prescription opioid misuse.
TEDS is not the only publicly available data source that may be used to track
national trends in opioid-related morbidity. The National Survey on Drug Use and Health
(NSDUH) from SAMHSA is a nationally representative survey collecting information on
drug use and mental health in non-institutionalized adults.76 These data permit
evaluation of state-level policies related to both non-medical use of prescription drugs
as well as illicit drugs. The Researched, Abuse, Diversion and Addiction-Related
Surveillance (RADARS) System consists of eight separate datasets that may also be used
to study a variety of opioid-related morbidity outcomes.77 RADARS is an independent
nonprofit organization that collects data on trends in drug misuse treatment, diversion,
and opioid related poisonings amongst other things.77 Finally, the Drug Abuse Warning
Network (DAWN) which is also administered by SAMHSA captures data on ED visits in
which illicit or prescription drugs are a cause or contributing factor. 78 DAWN offers
nationally representative estimates of ED visits related to drugs as well as regional
estimates for certain metropolitan statistical areas.
TEDS
In 2006, Simeone and Holland were the first to use TEDS data to assess the
impact of PDMPs on rates of prescription opioid misuse.79 State-level measures of
opioid misuse were defined as the number of TEDS admissions for prescription opioids
divided by the corresponding population in each state in each year. The authors did not
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investigate the impact of PDMPs on TEDS admissions directly, but rather constructed an
aggregate model in which they assessed the impact of PDMPs on supply of Schedule II
opioids and then estimated how changes in opioid supply effect changes in rates of
TEDS treatment admissions related to prescription opioid misuse from 1997-2003.
Results showed that PDMPs significantly reduced per capita supply of Schedule II
opioids and in so doing, significantly reduced the probability of prescription opioid
treatment admissions in PDMP states.79 The authors also found that this effect was
particularly pronounced in states with PDMPs that proactively monitored prescribing
and generated unsolicited reports.79 Interestingly, Simeone and Holland observed that
the annual prescription opioid admission rate was higher, on average, in PDMP states
than non-PDMP states, but argued that in the absence of these programs, the
probability of misuse would be even higher in PDMP states.79 This suggests that the
states with the worst relative magnitude of opioid misuse may be the first to implement
PDMPs.
Reisman et al. also used TEDS data to model the impact of PDMPs on
prescription opioid misuse, but did so with a vastly different methodology than Simeone
and Holland. While Simeone and Holland used the rate of opioid admissions per capita
as the outcome of interest, Reisman et al. defined the rate of ‘prescription opioid abuse’
as the number of TEDS prescription opioid admissions per 100 total treatment
admissions observed in TEDS.41 Reisman et al. conducted two distinct analyses: one in
which they used a time series linear regression to model the annual percent change in
opioid treatment admissions per year, and a separate cross-sectional analyses in which
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they used a logistic regression to assess the odds of reporting prescription opioids as the
primary drug of misuse by TEDS patients in PDMP states relative to non-PDMP states.
Results of the study showed that from 1997 – 2003, PDMP states had lower increases in
the rate of opioid admissions relative to non-PDMP states but this association was not
statistically significant.41 The authors also observed that the odds that a patient entering
treatment reported prescription opioids as the primary drug of misuse, was nearly 30%
higher in non-PDMP states relative to states with PDMPs.41
More recently, in 2017, Branham used TEDS data to examine associations
between the number of treatment admissions where patients reported heroin as their
primary drug used, and the number where patients reported prescription opioids as
their primary drug used, following implementation of PDMPs. The author hypothesized
that post-PDMP implementation, reduced admissions for prescription opioids would be
associated with increased admissions for heroin treatment. Branham utilized an
autoregressive integrated moving average model with a sample of 22 states from 1992 –
2012 to test this hypothesis. Results of the study showed a statistically significant, and
positive, association between increasing prescription opioid and heroin admissions
following implementation of PDMPs.80 The author concedes, however, that these results
do not answer the question of whether PDMPs are associated with increasing use of
heroin, only that they are positively associated with individuals entering treatment.
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NSDUH
Ali et al. used the NSDUH data in a 2017 analysis to examine associations
between PDMP implementation and trends in both prescription opioid misuse and
heroin use from 2004 – 2014. The authors modeled both outcomes as binary variables
indicating any nonmedical opioid use or heroin use, as well as continuous variables
indicating the number of days of nonmedical opioid use or heroin use in the past year. 81
Binary outcomes were estimated using logit regression and continuous outcomes were
estimated using gamma generalized linear models with a log-link function. The primary
independent variable of interest was whether states had operational PDMPs, and the
authors further categorized PDMPs by whether they had requirements for prescribers to
register with, or query, the PDMP in certain situations. Results indicated that PDMP
implementation was not associated with nonmedical prescription opioid use or heroin
use in the binary models. However, in the continuous models, the authors did find
associations between PDMP implementation and decreases in the number of days of
nonmedical opioid use and increases in the number of days of heroin use reported in
the past year.81 These associations were stronger in states that had operational PDMPs
that required prescribers to register with, or query, the PDMP data.
RADARS
In 2012, Reifler et al. used RADARS data to assess the impact of PDMPs on both
rates of prescription opioid misuse and intentional opioid poisonings. The Opioid
Treatment dataset in RADARS consists of data from seventy-four treatment centers in
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33 states and captures information regarding participants’ demographics and opioid
misuse history.77 The RADARS Poison Center data consists of data from 48 of the 60
total poison control centers in the US and tracks information on calls reporting
intentional opioid poisonings—note that ‘intentional’ here refers to the actual
medication use and not necessarily to the poisoning itself being intentional.77 Two
separate models were constructed, with one modeling changes in opioid misuse defined
as the rate of opioid-related treatment admissions from the Opioid Treatment data, and
the other modeling changes in opioid-related poisoning defined from the Poison Center
data. Both models used negative binomial regressions with the rates of opioid misuse or
poisoning from 2003-2009 as the outcomes of interest. Results showed that states with
PDMPs had significantly lower increases in the rate of opioid related poisonings
(average annual increase in non-PDMP states 8% vs. 0.8% in PDMP states) and also had
non-significantly lower increases in the rate of opioid misuse relative to states without
PDMPs.82 The authors also conducted a sensitivity analysis that differentiated states
with standard PDMPs vs. five states deemed to have ‘superior’ PDMPs. Results of the
sensitivity analysis were consistent with the main analyses but effects did not maintain
their statistical significance.82 This sensitivity analysis suggests that states with
particularly comprehensive PDMPs do not fare better than other states with PDMPs.
However, this finding may be due to the relatively small sample included in the ‘superior
PDMP’ group or because the authors fail to take into account temporal changes to the
PDMPs—i.e. the states with superior PDMPs did not necessarily have these ‘superior’
characteristics for the entire study period.
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DAWN
More recently, in 2015, Maughan et al. sought to examine associations between
PDMP implementation and prescription opioid-related ED visits using DAWN data.83 The
authors estimated rates of opioid-related ED visits for 11 geographically diverse
metropolitan areas on a quarterly basis from 2004 – 2011. A generalized estimating
equation Poisson regression model with a first-order autoregressive working covariance
matrix was used to model the outcome of interest. The authors defined a PDMP as
being operational when it allowed prescribers access to the PDMP data. Other
covariates of interest included the unemployment rate in each metropolitan statistical
area, as well as indicators for each metro area and calendar quarter, and an interaction
term between the metro area and calendar quarter. Results of the study indicated that
PDMP implementation was not significantly associated with the rate of prescription
opioid-related ED visits.84 However this study suffered from several prominent
limitations. First, the study was limited in sample size, and only included 11
metropolitan areas. Second, the authors failed to take into account the heterogeneity of
individual PDMP characteristics in these areas. And third, the authors did not investigate
the effect of an interaction between the PDMP indicator variable and calendar time.
Administrative Health Claims Data
Interest in the impact of PDMPs on prescription opioid-related poisonings
persisted in the wake of Refiler et al.’s and Maughan et al.’s studies, and was again
assessed in 2016 by Meara et al.85 Meara and colleagues used Medicare claims data to
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study the impact of PDMPs on nonfatal prescription opioid-related poisonings in a
population of disabled fee-for-service Medicare beneficiaries from 2006-2012. Nonfatal
prescription opioid-related poisonings were identified from emergency department and
inpatient claims where the primary or secondary diagnosis code corresponds to an
opioid-related poisoning, excluding heroin related poisonings. The authors used logistic
regression to model the odds of having an opioid-related poisoning while controlling for
residence in a PDMP state and other clinical and demographic characteristics. Results of
the study showed that individuals living in PDMP states did not have significantly
different odds of experiencing an opioid-related poisoning relative to individuals in nonPDMP states.85 The primary limitation of this study was that it only included a
population of disabled Medicare beneficiaries, so the generalizability of these results to
the overall US population is questionable.
1.3.3 Associations between PDMPs and opioid-related mortality
Several of the studies discussed in the previous section chose to focus on
associations between PDMP implementation and trends in nonfatal opioid-related
poisonings. Since 2010 however, additional studies have examined the impact of PDMPs
on opioid-related mortality. While one of the initial studies on this topic was conducted
using DAWN data and one with state specific mortality data, most have relied on the
National Vital Statistics System’s underlying cause of death data. Organized by the CDC,
the Wide-ranging Online Data for Epidemiologic Research (WONDER) is a web
application consisting of 20 collections of public-use data files related to US births,
deaths, and disease specific trends.86 The mortality data presents state-year specific
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estimates of the underlying cause of death listed on death certificates, as coded by
medical examiners. WONDER also includes demographic data from the Census Bureau,
so it is commonly used to analyze trends in disease specific death rates across the US.86
Paulozzi and Stier’s 2010 descriptive manuscript was the first to directly examine
associations between PDMP status and rates of opioid-related mortality.87 The authors
used DAWN data to compare rates of opioid-related mortality in New York and
Pennsylvania—two states with similar populations but radically different PDMPs.
Paulozzi and Stier report that in 2007, the prescription opioid mortality rate was nearly
three times higher in Philadelphia than in New York City.87 The authors argue that this
difference may be due, in part, to the fact that New York had a much more
comprehensive PDMP at the time than Pennsylvania. Notably, this was only a
descriptive study that did not include any statistical testing and only included a crosssectional assessment of two metropolitan areas over a period of one year.87
Building off the hypothesis proposed in his 2010 study, Paulozzi and colleagues
conducted a robust methodological study in 2011 assessing the impact of PDMPs on
rates of fatal opioid-related poisonings using national mortality data from 1999 – 2005
from the CDC WONDER data.67 The authors calculated state-year rates for both overall
drug poisoning deaths as well as prescription opioid-related deaths. Panel regression
techniques were used to model the impact of PDMPs on year-to-year changes in the
rates of prescription opioid and overall drug poisoning deaths. Importantly, the authors
differentiated between states with PDMPs that sent proactive reports to prescribers,
dispensers, or law enforcement, and those that did not require proactive reporting.
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Results of the study showed that presence of a PDMP was not a significant predictor of
changes in either overall drug mortality or prescription opioid-related mortality.67 The
authors also found that proactive PDMP states did not have significantly lower rates of
either outcome than other states with PDMPs.67 Finally, it was observed that New York,
California, and Texas—the three states with historical serialized prescription forms—had
substantially lower rates of both overdose outcome relative to all other states. 67
A more recent study by Delcher et al., used a slightly different methodology to
assess the impact of PDMP implementation on the rate of oxycodone-caused mortality
in the state of Florida.88 Delcher and colleagues received data from the Florida Medical
Examiners Commission on all drug-related deaths in the state from 2003-2012. The main
outcome of interest consisted of monthly counts of deaths caused by oxycodone, not
including deaths where oxycodone was observed to be present in nonlethal quantities.
Notably, Florida is home to some of the top opioid prescribers in the country by volume,
and has also been noted to be the source of diverted oxycodone to several states. 88,89
Delcher et al. took two distinct approaches in modeling the PDMP variable. First, the
PDMP variable was modeled as a binary variable representing program implementation.
Next, it was modeled as the ‘health care provider query rate’, calculated as the total
number of queries per registered health care provider per month after implementation
of the PDMP. The authors used an autoregressive integrated moving average (ARIMA)
time series model to assess the impact of the PDMP on oxycodone-caused mortality
while controlling for external trends (i.e. national trends in opioid misuse) and internal
state-policy changes (i.e. operation pill nation). There was a statistically significant
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decline in oxycodone-caused mortality in the month after implementation of Florida’s
PDMP, and this effect persisted when controlling for the effects of other state-wide
policies and national trends.88 The authors also found that increases in the health care
provider query rate were associated with significant reductions in oxycodone-caused
mortality.88 This study was the first to find that PDMPs are significantly associated with
lower rates of fatal prescription opioid-related poisonings, however, the generalizability
of these results are limited because this study only describes a single state and also only
considered opioid-related poisonings caused by oxycodone.
In 2016, Patrick et al. used CDC WONDER data from 1999 – 2013 to examine
state-year rates of prescription opioid-related poisoning deaths per 100,000 residents.42
Patrick et al. made significant improvements over previous studies on this subject by
modeling the effects of specific PDMP characteristics. The authors used panel regression
models with state fixed effects, similar to the one used by Paulozzi et al. in 2011, to
assess the impact of PDMP implementation alone and also to examine the marginal
effects of different PDMP characteristics on the rate of prescription opioid-related
mortality. Patrick and colleagues were specifically interested in whether PDMPs that
monitored more CS schedules, required more frequent data reporting, and required
providers to register or query the data were associated with significant reductions in the
rate of fatal opioid-related poisonings. Results of the study show that PDMP
implementation was associated with a statistically significant reduction in the rate of
prescription opioid-related deaths.42 Furthermore, the authors also found that PDMPs
that monitored four or more CS schedules, or updated data at least weekly were
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associated with significantly greater reductions in the rate of opioid-related deaths
relative to programs without these characteristics.42
More recently, Pardo used CDC WONDER data from 1999 – 2014 to examine the
association between ‘strength’ of PDMPs and trends in prescription opioid-related
mortality.90 As in the Patrick et al. study, Pardo identified rates of fatal prescription
opioid-related poisonings at the state-year level. The author then classified PDMPs using
a numeric system that he created to describe the programs overall strength. This system
applies different points to features of the PDMP—e.g. 1 point if PDMPs allow access to
prescribers and 4 points if the PDMP requires prescribers to query the PDMP data in
certain situations. Two-way fixed-effects models were used to control for state-level and
time-dependent factors associated with trends in prescription opioid-related mortality.
The independent variable of interest—‘strength’ of the PDMP—was separately modeled
as both a continuous score as well as a categorical variable roughly defined by quartile
(e.g. having score 1-7, vs. 8-13 etc.). Results indicated that every 1-point increase in
PDMP ‘strength’ was associated with a 1% reduction in the rate of prescription opioidrelated mortality.90 Further, states in the third quartile of PDMP ‘strength’ were
associated with an 18% reduction in opioid-related death relative to states without
PDMPs.90 The primary limitation of this study however, is that the scoring system
created by the author is based solely on his personal judgement. Weights are applied to
several factors, such as having a data retention policy or oversight board, that have no
empirical evidence to suggest that they are associated with opioid-related mortality.
Further, the magnitudes of certain weights seem misappropriated. For example, having
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an appropriated funding mechanism was given three times the weight as allowing
prescribers or pharmacists to access the data.
Nam et al. also used CDC WONDER data in 2017 to examine associations
between PDMP implementation and trends in opioid-related mortality.91 The authors
identified all fatal prescription opioid-related poisonings in the WONDER data from 1999
– 2010 and created a time-varying binary indicator variable to define whether each
state’s PDMP was operational in a given year. Multivariate regression models were
constructed with state and year fixed effects as well as state-specific linear time trends.
This methodology differed from that used by Patrick et al. who constructed models with
state fixed effects and a single national linear time trend rather than state-specific
trends. Results of the study indicated that implementation of PDMPs was not associated
with rates of prescription opioid-related mortality relative to expected rates in the
absence of PDMPs.91 The primary limitations of this study are that the authors fail to
define what they considered as an operational PDMP, and they also failed to take into
account the heterogeneity of PDMP features—potentially explaining why their results
differed from those observed in the Patrick et al. study.42,91
1.3.4 Gaps in existing literature
PDMPs today are vastly different than the MCPPs that preceded them in the in
the early 20th century. As the United States finds itself amidst a surging prescription
opioid epidemic, modern PDMPs offer an unprecedented tool for public health and law
enforcement entities to monitor the prescribing of these medications while also
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allowing for the adequate treatment of chronic pain. The impact of PDMPs on opioid
related morbidity and mortality has been thoroughly researched, yet many of these
studies have found inconclusive evidence of their efficacy. Early studies found that
implementation of PDMPs was associated with reductions in publically funded TEDS
opioid treatment admissions, but not all results were statistically significant.41,79,82 A
recent study using NSDUH data found that PDMPs were associated with nonsignificant
decreases in the number of days of reported prescription opioid misuse and increases in
the number of days of reported heroin use.81 Only one of the three studies investigating
associations between PDMPs and trends in nonfatal prescription opioid-related
poisonings found that PDMPs were significantly associated with decreased rates of
poisonings.82,83,85 Finally, three of the five studies examining associations between
PDMP implementation and rates of prescription opioid-mortality found that the
programs were associated with lower rates of opioid-related deaths.42,67,88,90,91
This review has identified four common shortcomings of the existing PDMP
literature: 1. Many studies fail to clearly define when PDMPs are considered ‘active’ or
operational. 2. Most studies do not take into account the heterogeneity of individual
PDMP characteristics between states or changes to these characteristics over time. 3.
No studies to date have investigated the differential impact of PDMPs on prescription
vs. illicit opioid-related poisonings. 4. None of the previous research investigates
differential associations between PDMP implementation and trends in opioid-related
outcomes in populations with different types of insurance coverage.
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Generally, all PDMPs will experience three major transitions over the course of
their lives. First, state legislation is passed authorizing the creation of the PDMP.
Second, at some point after that legislation is passed, the PDMP will begin collecting
data on CS prescribing. This data collection may not begin for weeks or even years after
the initial legislation is enacted. Third, at some point users will be provided access to the
PDMP data. The time of user access may be simultaneous with the beginning of data
collection or again, it may not occur for months or years after the data collection has
begun. A PMDP may theoretically be considered ‘operational’ after any of these three
time periods, but unfortunately much of the existing PDMP literature is generally vague
about when they classify PDMPs as active. At least one study has explicitly controlled for
the time period during which PDMP legislation has been enacted but programs are not
yet operational—only to fail to define whether they consider operational to mean that
the PDMP is collecting data or that it has made that data available to prescribers. 42
Presumably, a PDMP will only really be able to achieve its intended purpose if it both
collects data and makes that data available to authorized users. Given that previous
research has failed to use a uniform date for defining when PDMPs are ‘operational’, it
is unsurprising that this research has found conflicting results
Failing to account for specific features of operational PDMPs also confounds the
results of previous research examining associations between PDMPs and trends in
opioid-related morbidity and mortality. This point was astutely made by Green et al. in a
prominent rebuke of Paulozzi et al.’s 2011 study of associations between PDMPs and
trends in opioid-related mortality.92 Green et al. argued that it was inappropriate for
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Paulozzi and colleagues to treat all PDMPs as homogenous programs that were either
‘on’ or ‘off’ given the fact that many of the programs included in their study had vastly
different programmatic features in terms of data availability and reporting
requirements.92 Although this criticism was published after one of the very first studies
examining PDMPs, authors have continued to neglect this heterogeneity in many more
recent studies. Also, some studies that do take into consideration specific features of
PMPDs, fail to account for temporal changes to these characteristics—i.e. a state
requiring proactive reporting now may not have required it when the PDMP was first
implemented.67,79,82 Neglecting to control for PDMP heterogeneity is also problematic
because it prevents researchers and policy makers from understanding which features
of PDMPs have the greatest impact on opioid-related morbidity and mortality. Several
groups have released PDMP best practice guidelines that offer advice on efficacious
operation of PDMPs, however there is a general dearth of empirical evidence to support
the guidelines that they recommend.55,69 As PDMPs grow and change over time, it is of
the utmost importance that empirical evidence exist to guide their evolution in the
future.
Almost all of the research to date investigating associations between PDMPs and
trends in opioid-related morbidity and mortality has focused exclusively on prescription
opioid-related morbidity and mortality. As trends in prescription opioid-related deaths
have levelled off in recent years, there has been an extraordinary increase in the rate of
heroin and illicit fentanyl-related mortality. As illicit opioid mortality has increased,
anecdotal suggestions that this increase is, in part, driven by PDMPs and other policies
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intended to decrease the supply of prescription opioids have surfaced. One previous
study found that PDMP implementation was associated with a statistically insignificant
increase in reported number of days of heroin use in the NSDUH data. 81 Another study
found a significant increase in the ratio of heroin deaths to prescription opioid deaths in
North Carolina from 2007 to 2013, however, this study did not investigate the role of
the state’s PDMP.93 As heroin deaths increase across the country, it is critical that
researchers and policy makers understand whether PDMPs play a role in this
burgeoning trend. Furthermore, if PDMPs are contributing to the heroin epidemic, it is
important to determine which features of PDMPs are most strongly associated with
trends in illicit opioid-related mortality.
In addition to elucidating associations between PDMP features and trends in
prescription and illicit opioid-related morbidity and mortality, it is also critical to
understand how features of these programs impact different populations. Much of the
previous research described above relies on de-identified mortality data or data from a
single payer source. As such, none of this research explores how PDMPs may
differentially impact populations with various types of insurance. As healthcare based
programs that operate at the point-of-care, it is plausible that operational PDMPs and
PDMPs with certain features will exert differential impacts on trends in opioid-related
morbidity and mortality in different insurance beneficiary populations. Privately insured
individuals and Medicare beneficiaries have frequent engagement with the healthcare
system and thus present many opportunities for PDMPs to intervene and stymie opioidrelated morbidity in these populations. On the other hand, previous research shows that
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uninsured individuals and Medicaid beneficiaries have the greatest odds of suffering
from opioid use disorder (OUD) relative to other insurance beneficiaries, so it is also
plausible that PDMPs could exert a more tangible impact on these populations. 94
1.4 Conclusion
Despite the plethora of research examining associations between PDMPs and
trends in opioid-related morbidity, this review has identified four common shortcomings
in this previous work that may explain the inconclusive evidence of PDMP efficacy. 1.
Many studies fail to clearly define when PDMPs are considered ‘active’ or operational. 2.
Most studies do not take into account the heterogeneity of individual PDMP
characteristics between states or changes to these characteristics over time. 3. No
studies to date have investigated the differential impact of PDMPs on prescription vs.
illicit opioid-related poisonings. 4. None of the previous research investigates
differential associations between PDMP implementation and trends in opioid-related
outcomes in populations with different types of insurance coverage.
Together, these shortcomings represent potential confounding factors in
previous studies as well as significant gaps in the existing body of literature. This
dissertation will address each of these issues in turn, using robust epidemiological
methods with multiple data sources. Chapter 2 uses administrative health claims data
from a nationally representative sample of privately insured adults to address the first,
second, and third shortcomings listed above. Chapter 3 uses hospital discharge data
from all payer types to address the first, second and fourth shortcomings identified in
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this review. The final chapter of this dissertation will summarize how the key findings
from these studies address gaps in previous research, and will explore the policy
implications of these findings and make recommendations for future research.
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A brief note on language used to describe prescription and illicit opioid-related
poisonings
This dissertation is primarily interested in associations between PDMPs and
trends in prescription and illicit opioid-related poisonings. Prior to delving into the
research, however, it is important to pause and briefly discuss what exactly these terms
are referring to. Use of the terms ‘prescription opioid-related poisoning’ (PORP) and
‘Illicit opioid-related poisoning’ (IORP) is inspired by the official CDC guide to ICD-9-CM
codes related to poisonings.95 This guide uses these exact terms to differentiate
between poisonings related to prescription opioids and those related to ‘illicit’ opioids,
which it defines as ‘opium and heroin’. However, it is important to note that these terms
fail to capture the reality that PORPs may include illicit use of prescription opioids, and
IORPs may misclassify use of adulterated prescription opioids. This is particularly
relevant due to recent increases in rates of fentanyl-related poisonings. Fentanyl is a
prescription opioid that may be illicitly manufactured and sold as heroin.96 In these
cases, fentanyl-related poisonings that are technically PORPs may be miscoded as IORPs
in administrative claims data. Alternatively, certain types of fentanyl that are
manufactured in China and sold in the US are not used in legitimate medical practice
here, and in this sense should rightfully be considered ‘illicit opioids’.96 Unfortunately,
the ICD-9-CM codes used to identify PORPs and IORPs in these studies are not specific
enough to identify the underlying drugs causing the poisoning—this limitation is
discussed in more detail in section 2.5. Please be aware moving forward that my use of
the terms IORP and PORP is strictly referring to these codes as described in the CDC
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guide to ICD-9-CM codes related to poisonings. Further, my use of these terms is not
intended to make any comment on the actual legality of the substances resulting in
PORP or IORP codes, nor the legality of use of the substances resulting in these codes.
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Chapter 2: Associations Between PDMP Features and Trends in Prescription and Illicit
Opioid-Related Poisonings In a Population of Privately Insured Adults
2.1 Introduction
From 1999 to 2010, opioid analgesic prescriptions in the US increased
approximately 4-fold.9 Increasing use of opioid analgesics has been associated with a
corresponding increase in rates of prescription opioid-related poisoning (PORPs).10
Deaths involving PORPs quadrupled from 1999 to 2015, killing more than 183,000
people over this time period.2 Opioid-related inpatient hospital admissions and
emergency department (ED) visits also increased substantially from 2005-2015.97 In
February 2011, the US Centers for Disease Control and Prevention (CDC) labelled recent
increases in PORPs as “a US epidemic”.1 Figure 2.1 from the CDC displays the rate of
opioid poisoning-related mortality by type of opioid from 2000 – 2016.
In recent years, increases in PORP rates have been dwarfed by even larger
increases in rates of heroin-related poisonings (henceforth referred to as illicit opioidrelated poisonings or IORPs).2 Previous research has found increases in rates of heroin
use across the US, and particularly dramatic increases among white, middle aged
individuals living in rural areas.98,99 Many individuals who currently use heroin began by
first engaging in nonmedical use of prescription opioids.98,100 Surveys with heroin users
reveal that many have chosen to substitute heroin for prescription opioids due to the
increasing cost and reduced availability of prescription opioids. 98
PDMPs are state-based programs that track the prescribing and dispensing of
controlled substances (CS) to consumers with a goal of mitigating misuse and
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diversion.101 Chapter 1 contains an in-depth review of the history and evolution of
PDMPs. Ideally, PDMPs offer the opportunity for providers to adequately manage pain
with opioid analgesics while also providing a barrier to prescription opioid misuse.
PDMPs are programs that fundamentally act to restrict the aggregate availability, or
supply, of prescription opioids, and thus may be considered ‘supply side’ interventions.
Recently, Some pundits and journalists have anecdotally reported that by reducing the
availability of prescription opioids, PDMPs—and specifically PDMPs with particular
robust features—may be driving individuals to use heroin rather than prescription
opioids and thus may in part be responsible for increasing rates of IORPs.102-106
In general, all PDMPs operate similarly. Data generated at the time of medication
dispensing is uploaded to a central data server that is accessible to authorized users.
Though all programs have this same basic functionality, it is well known that there is
tremendous heterogeneity between states in terms of individual PDMP features. 20,54,107
PDMPs may vary in terms of CS Schedules monitored, reporting requirements, and
whether prescribers are required to use the PDMP data, among other characteristics.
These specific PDMP features may have important impacts on the efficacy of individual
programs. For example, a PDMP that monitors all CS Schedules, requires dispensers to
report CS dispensing on a daily basis, generates unsolicited reports for prescribers, and
requires prescribers to query the data before issuing CS prescriptions, may allow for
easier detection of potential medication misuse or diversion relative to less
comprehensive programs.69,108-110
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Though there have been many previous efforts to examine associations between
PDMP implementation and trends in PORP rates, only two of these studies have
specifically examined the impact of different PDMP features. A 2016 study by Patrick et
al. utilizing CDC WONDER data from 1999 – 2013 found that PDMPs that monitored four
or more CS schedules, and updated data at least weekly were associated with
significantly greater reductions in the rate of opioid-related deaths relative to programs
without these characteristics.42 In a more recent study also utilizing CDC WONDER data,
Pardo quantified PDMP ‘strength’ by creating a numeric system that assigned weights to
different features of operational PDMPs. Pardo did not investigate the impact of
individual features, but found that every 1-point increase in PDMP ‘strength’ was
associated with a 1% reduction in the rate of prescription opioid-related mortality.90
Recently, there has also been interest in associations between PDMP
implementation and trends heroin use. Ali et al. found that implementation of PDMPs
was associated with a nonsignificant increase in the number of days of reported heroin
use in respondents to the National Survey of Drug Use and Health (NSDUH). 81 In a nonpeer reviewed report, Justine Mallat found that PDMP implementation had a
heterogeneous impact on rates of heroin-related crime incidents in a sample of 38
states.111 Finally, in a 2017 study using TEDS data, Branham found that after PDMPs
were implemented there was a positive association between number of patients
reporting prescription opioids and number of patients reporting heroin as their primary
drug used.80 This finding goes against the theory that increasing heroin use is related to
decreases in prescription opioid use following PDMP implementation. Taken together,
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these studies suggest that PDMPs may be associated with increases in heroin use, but
none offer convincing evidence that PDMPs are driving the recent increases in IORPs.
Despite the plethora of research examining the impact of PDMPs on the US
opioid epidemic, several prominent gaps remain to be addressed. First, only one study
to date has explored associations between individual PDMP features and trends in
PORPs. Second, no research has examined differential associations between PDMP
implementation and trends in rates of PORPs vs. rates of IORPs. The study presented in
this chapter addresses both of these gaps and is also the first to specifically examine the
impact of PDMP implementation in a population of privately insured adults. The specific
aims of this study were to: I. Examine associations between specific features of
operational PDMPs and trends in PORPs in a nationally representative sample of
privately insured adults; and II. Assess associations between PDMP features and trends
in IORPs over time in the same population of privately insured adults.
Please note that this study consisted two related but distinct analyses. The
separate components of this study utilized nearly identical methodology to assess the
two outcomes of interest. For the purposes of brevity and clarity, the methodology and
discussion of these analyses are presented in tandem however the results are described
separately.
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2.2 Methods
2.2.1 Study Design
This observational longitudinal study employed a ‘natural experiment’ design to
assess associations between PDMP features and rates of PORPs and IORPs in a
nationally representative sample of privately insured adults. Natural experiments are
empirical studies wherein subjects are exposed to an intervention that is outside the
control of the investigator.112 Changes in PDMP features—including timing of initial
legislation enactment and program implementation, or alterations to specific
functionality—were assessed monthly in all 50 states and the District of Columbia from
January 2004 to December 2014. PDMP status was assessed on a monthly basis as
changes in PDMP features occurred frequently and at irregular times during the study
period. The unit of observation was the state-month, and including 51 states over an 11
year period, the final dataset included 6,732 state-month observations. As discussed
above, this study had two distinct outcomes of interest, the first being the number of
PORPs and the second being the number of IORPs among the beneficiary population in
each state-month from 2004 – 2014. The relative risk of PORP and IORP was calculated
for each state-month during this period while controlling for specific PDMP features as
well as demographic and clinical characteristics of the study population observed in
each state-month. Given that this study was observational and relied on de-identified
data collected for research purposes, it was deemed exempt from review by the
University of Kentucky IRB.
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2.2.2 Data
This study utilized data from a variety of sources. Data regarding clinical events
as well as the demographic and clinical characteristics of the privately insured adult
population were obtained from the Truven Health Marketscan® Commercial Claims and
Encounters database.113 Truven offers fully integrated pharmaceutical and medical
administrative claims data with relevant health plan enrollment and demographic
information. These data are nationally representative of the non-institutionalized
privately insured and employed US population, and include all provider, facility and
pharmaceutical claims for eligible beneficiaries. Truven collects data from a wide variety
of insurance providers as well as large self-insured employers and includes data on
approximately 20 – 30 million distinct individuals each year. All individuals who were
aged 18 or over and were enrolled for at least one full month with pharmacy and
medical benefits at some point from 2004-2014 were included in the study population.
Individual patient claims and demographic data were aggregated into rates and
percentages at the state-month level.
Data regarding the status of PDMPs in each state-month were gleaned from two
separate data sources—the National Alliance for Model State Drug Laws (NAMSDL) and
the Prescription Drug Abuse Policy System (PDAPS). NAMSDL is a non-profit group that
receives funding from the federal government to assist in the planning and
enhancement of PDMPs and also publishes resources regarding the past and present
status of PDMPs.21 PDAPS is a research tool funded by the National Institute on Drug
Abuse (NIDA) to track state laws related to prescription drug abuse. 114 The NAMSDL and
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PDAPS data were both used to assess the timing of PDMP legislation enactment and
program operation. Data regarding the status of specific PDMP features, and dates that
these features were implemented, were obtained from PDAPS. These data sources are
both commonly used in longitudinal studies examining PDMPs.42,67,81,82,90,115
2.2.3 Outcome and Covariate Measures
This study examined two distinct outcomes of interest, the first being the count
of PORPs observed in each state-month and the second being the count of IORPs
observed in each state-month. Since these outcomes were assessed in a similar manner,
they are henceforth referred to collectively as ‘poisonings’ for the remainder of this
section. Poisonings were identified from inpatient hospital admissions and emergency
department visit claims where at least one code for either poisoning type was listed.
Hospital admissions were identified using the inpatient hospital admissions claims file
from Truven, and emergency department visits were identified as inpatient or
outpatient claims where the place of service code was marked as ‘23’. The CDC guide to
ICD-9-CM codes related to poisoning and pain was used to identify ICD-9-CM codes for
PORPs and IORPs.95 Table 2.1 presents the ICD-9-CM codes used to identify PORPs and
IORPs. Since patients experiencing a poisoning often have multiple claims where the
poisoning is listed as a diagnosis, rigorous methods were employed to avoid double
counting poisoning events. Only one PORP or IORP was counted per patient per day.
Patients who had both a PORP and IORP diagnosis listed on the same claim were
counted as having a PORP as well as an IORP on that day. Any poisoning diagnosis
observed in outpatient claims were required to have the place of service listed as ED as
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routine follow-up care from an initial poisoning is unlikely to occur in the ED setting.
Finally, hospital admission claims with a poisoning diagnosis that had the same
admission date as a preceding poisoning-related hospital admission’s discharge date
were not counted, as these likely represent transfers from one institution to another.
Demographic covariates of interest in this study included the percentage of the
enrolled Truven population in each state-month that were male, the percentage that
were aged 25 – 35, and the geographic region of each state. For calculating percentages
at the state-month level, the denominator was the total number of person-months of
eligibility in each state month. Eligibility was defined as being enrolled for an entire
month with both pharmacy and medical benefits. For example, the number of male
person-months was divided by the total number of person-months observed in a given
state-month to determine the percentage of the population that were male in that
state-month. These covariates were chosen as they are the only demographic
characteristics available in the Truven data. The percentage of beneficiaries aged 25-35
was chosen as a covariate over other age groupings because this group experienced the
highest rates of drug overdose deaths in 2016.3 Geographic region was defined
according to US Census Bureau regions.116
The only clinical covariate included in this study was the rate of diagnosed
substance use disorder (SUD) observed in each state-month. SUD diagnoses were
defined according to Clinical Classification Software (CCS) grouping 661 from the
Healthcare Cost and Utilization Project (HCUP).117 CCS is a diagnosis categorization
scheme that groups ICD-9-CM codes into clinically meaningful categories, and group 661
45

includes diagnoses related to SUD.117 The rate of SUD in each state-month was
calculated as the number of person-months in which at least one diagnosis from CCS
group 661 was observed, per 100,000 total person-months observed in that statemonth. This was chosen as a covariate of interest as diagnosed SUD is a known risk
factor for PORP.118,119
Enactment of PDMP legislation may induce changes in prescribing practices
before the programs are formally operational.42 In order to adjust for this possibility,
this study was careful to distinguish the date that PDMP legislation was enacted and the
date that programs became formally operational. For the purposes of this study, PDMPs
were defined as being operational when they made data available to prescribers or law
enforcement officials. Dates of PDMP legislation enactment as well as dates of data
availability are reported by both NAMSDL and PDAPS, however, the dates that these
groups report are at times inconsistent. To address this shortcoming, the date of PDMP
legislation enactment was conservatively defined as the earliest date reported by one of
these groups and the date that PDMPs became operational was conservatively defined
as the latest date reported by one of these groups. The PDAPS data were used when
dates were not available from NAMSDL.
Data regarding the status of specific PDMP features, and dates that these
features were implemented, were obtained from PDAPS. This study examined five
distinct features of PDMPs: 1. Whether the PDMP was operational—defined as
prescribers or law enforcement having access to the data; 2. CS Schedules monitored by
the PDMP (II only or II-III, II-IV, and II-V); 3. Frequency of data reporting from dispensers
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to the PDMP central server (monthly or less, weekly, and daily); 4. Requirement for
unsolicited reporting of patients’ CS prescription history to in-state prescribers or
licensure boards; and 5. Mandated (as defined by PDAPS) prescriber query of PDMP
data prior to prescribing in certain circumstances. Other PDMP features of interest,
including mandatory registration with the PDMP and PDMP utilization rate by
prescribers, were not included in the study due to data constraints. Nebraska is the only
state with an operational PDMP that does not require dispensers to report data to the
PDMP central server.66 Because it is the only PDMP that is entirely voluntary, it was
excluded from the present analysis.
Each of the five PDMP variables were coded to reflect when no PDMP legislation
had been enacted, PDMP legislation was enacted but the program was not yet
operational, and finally when the PDMP was operational with a given level of the
covariate. For example, the variable for requirement of unsolicited reporting of patients’
CS prescription history was coded as: 0= No PDMP, 1= PDMP enacted but not
operational, 2= PDMP operational without unsolicited reporting, and 3= PDMP
operational with some unsolicited reporting. Each PDMP characteristic of interest, and
its constituent levels are presented in Table 2.2. Changes to specific PDMP features
were assessed monthly and a set of time varying indicator variables were created to
describe PDMP features in each state-month. Variables were coded to reflect the first
full month that a given feature was in place.
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2.2.4 Statistical Analysis
Generalized estimating equation (GEE) Poisson regression models were fit to
estimate the risk of PORP and IORP associated with PDMP features while adjusting for
demographic and clinical characteristics of the privately insured Truven population.
While some previous studies have used negative binomial regression methods to model
counts of drug-related poisonings, over-dispersion was not a significant problem in
these data (the deviance divided by the degrees of freedom ranged from 1.042 – 1.425
in the models investigated) and so the simpler Poisson regression model was used
instead.82,120 The unit of analysis was the state-month and the modeled outcomes of
interest were the monthly counts of PORP and IORP observed in each state-month.
Adjusted models were derived separately for the two distinct outcomes of interest for
each of the five PDMP features. This study was fundamentally interested in examining
whether certain PDMP features may be more strongly associated with trends in PORP
rates than other features. With this in mind, separate models were fit for each PDMP
feature to provide greater granularity in terms of the relative impacts of each feature.
Thus the primary results of this study are presented in the form of ten separate adjusted
GEE models—five investigating associations between PORPs and PDMP features, and
five investigating associations between IORPs and PDMP features.
All ten adjusted GEE models relied on the same assumptions and were specified
in a similar manner—the only difference being the particular PDMP feature variable
included in the model. Each model included one PDMP feature, as well as variables for
time (coded as the number of months since the study period began, i.e. January 2004 =
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0 December 2014 = 132 etc.), geographic region, rate of diagnosed SUD, percentage of
the population that were male, and percentage of the population that were aged 25-35
years old. State-month Truven beneficiary population counts expressed as natural
logarithms were used as an offset term in each model to adjust for variation in Truven
population sizes for any given state-month. Robust standard errors were calculated to
adjust for repeated measures from each state. The monthly covariance structure in each
state was selected as a first-order autoregressive process to account for
autocorrelations in the time series.121
Each adjusted GEE model also included an interaction between the PDMP
feature of interest and time, to model the risk difference in PORP or IORP over time in
states with and without the given PDMP feature. These models are interpreted as fitting
multiple summary regression lines to the data. The differences in intercepts between
these lines addresses baseline differences (at month= 0, or January 2004) in mean rates
of PORP and IORP in states with and without the PDMP feature of interest. Differences
in slopes—as characterized by the parameter estimate for the interaction term—
represent the different trends in PORP and IORP over time for states at different levels
of the PDMP feature of interest. As mentioned above, Nebraska was excluded from all
statistical analyses because it is the only state with a voluntary PDMP.
The Poisson regression models were fit in SAS Enterprise Guide version 5.1 using
PROC GENMOD with the REPEATED statement to implement the GEE approach.
Reference coding scheme was used in regression parameter estimates allowing
calculation of the adjusted relative risk (aRR) for PORP and IORP associated with each
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variable by exponentiation of the relevant parameter estimate. Statistical significance
was assessed as p < 0.05 for all analyses. Figures were generated using SAS Enterprise
Guide version 5.1, Tableau version 10.3, and JMP version 12.
2.2.5 Sensitivity Analyses
Naloxone Access Laws
Naloxone is an FDA approved prescription medication that can be used to
reverse the effects of an acute opioid-related poisoning.122 In recent years, states have
begun to enact legislation to increase the availability of naloxone for family, friends, and
other potential bystanders of opioid-related poisonings.123 At present, all states have
enacted some sort of legislation to remove legal barriers to naloxone access. 123 Most
commonly, states have begun to permit naloxone prescribing to individuals other than
the person at risk of opioid-related poisoning, or have otherwise removed the need for
a person to see a prescriber before obtaining the medication.123 Implementation of
these ‘naloxone access laws’ may be associated with aggregate trends in opioid-related
poisonings.90,124 With this in mind, this study implemented a sensitivity analyses to
control for the presence of Naloxone access laws at the state level. Data on the timing
of naloxone access law implementation were gathered from PDAPS.125 A binary dummy
variable was created to describe whether states had any type of naloxone access laws in
place for the majority of each year from 2004 – 2014. The GEE Poisson regression
models discussed in the statistical analysis section above were re-fit including this
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variable in order to assess whether naloxone access laws attenuate associations
between PDMP features and trends in PORPs and IORPs.
Buprenorphine Prescribing
Buprenorphine is an FDA approved medication used to treat opioid dependence
by preventing symptoms of withdrawal from heroin and other opioids.126 Previous
research has demonstrated that, at the individual level, buprenorphine use is associated
with a protective effect on risk of opioid-related poisonings.127-129 In the United States,
physicians interested in prescribing buprenorphine must apply for a waiver from the
registration requirements of the Controlled Substance Act and also must complete
required training.130 The number of waivered physicians eligible to prescribe
buprenorphine has increased rapidly in recent years.130-132 Similarly, the percentage of
opioid treatment programs offering buprenorphine increased from about 11% in 2003
to approximately 58% in 2015.133 With this in mind, this study implemented a sensitivity
analysis to adjust for aggregate rates of buprenorphine prescribing at the state-month
level. Due to data constraints, rates of buprenorphine use could only be calculated for
the years 2009 – 2014. Buprenorphine prescribing was identified from outpatient
pharmacy claims data using GPI codes. Both mono (buprenorphine hydrochloride) and
combination (buprenorphine hydrochloride and naloxone hydrochloride) buprenorphine
formulations were included in the analysis. The rate of buprenorphine use was defined
as the number of individuals receiving at least one buprenorphine prescription in each
state-month per total 100,000 individuals observed in each state-month. The GEE
Poisson regression models discussed in the statistical analysis section above were
51

initially re-fit only including observations from 2009 – 2014. Results from these models
were compared to results of GEE models that included the buprenorphine prescribing
rate in each state-month as an additional covariate.
2.3 Results
2.3.1 Changes to PDMPs
There was a substantial increase in the number of states with operational PDMPs
over the study time period. Figure 2.2 presents a visualization of when PDMP legislation
was enacted and when programs became operational in each state from 2001 – 2014.
While 13 states had operational PDMPs in December 2014, 47 states and the District of
Columbia had operational PDMPs at the end of 2014. This time period also saw many
changes to important characteristics of operational PDMPs. Table 2.3 displays the
number of states with operational PDMPs with certain features in place for the majority
of the year in each year from 2004 – 2014. In 2004, only 2 of the 13 (15.4%) operational
PDMPs required weekly or daily data reporting from dispensers, but by 2014, 38 of the
47 (80.9%) operational PDMPs had this feature in place. PDMPs also experienced an
increase in the number of drug schedules monitored. In 2004 nearly one-third of
operational PDMPs only collected data on Schedule II, or Schedules II + III Controlled
Substances, however, in 2014 all operational PDMPs monitored either Schedules II – IV
or all Schedules II – V. PDMPs that sent unsolicited reports to prescribers, law
enforcement, or licensure boards, as well as PDMPs that required prescribers to query
the PDMP data in certain situations also became more popular in recent years. In 2014,
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nearly 40% of operational PDMPs required unsolicited reporting while only 15.4% had
such a requirement in 2004. Finally, no states required prescribers to query the PDMP
data in 2004 but in 2014 nearly 20% of operational PDMPs had this requirement in
place.
From January 2004 – December 2014 there were 6,600 state-months observed,
with 3,858 (58.5%) of those state-months having operational PDMPs in place, and 1,111
(16.8%) having PDMP legislation enacted without operational programs. Table 2.4
presents descriptive statistics of the state-months included in the study population,
stratified by PDMP status. Over the 6,600 state-months, there were over 2.6 billion
person-months observed. The mean percent of the Truven population that were male,
and the mean percent aged 25 – 35 was generally consistent among state-months with
and without operational PDMPs. However, substantial variation in the mean rate of
diagnosed SUD was observed. State-months without PDMPs had a mean rate of
diagnosed SUD of 66.78 per 100,000 person-months observed, while state-months with
operational PDMPs had a mean rate of 151.66 per 100,000, and state-months with
PDMP legislation enacted without operational programs had a mean rate of 102.58 per
100,000.
2.3.2 PORP Specific Results
Over the eleven year study period there were a total 40,766 distinct PORPs
observed. The overall rate of PORP from 2004 – 2014 was 1.52 per 100,000 person
months observed. This rate was calculated as the total number of PORP events per
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100,000 person-months observed over the entire study period. Figure 2.3 displays the
overall PORP rate in each year from 2004 – 2014. There was a statistically significant (p <
0.0001), 108% increase in the mean PORP rate over the study period, from 0.92 per
100,000 person-months in 2004 to 1.92 per 100,000 person-months in 2014. These
rates were calculated as the average PORP rate observed in all state-months in 2004 and
2014. Figure 2.4 presents the trends in overall annual PORP rate stratified by PDMP
status. This was calculated as the mean PORP rate for all state-months with a given
PDMP status in each year. This figure shows that state-months with operational PDMPs
had slightly higher overall PORP rates in 2004 relative to state-months without PDMPs
(0.946 vs. 0.896 per 100,000 person-months). Again, overall rates were calculated as the
total number of PORP events observed in state-months with a given PDMP status, per
100,000 person-months observed in those state-months. Though there was a consistent
increase in overall PORP rates for all groups from 2004 – 2014, state-months with
operational PDMPs had a markedly lower overall PORP rate in 2014 than state-months
without PDMPs (1.792 vs. 2.073 per 100,000 person-months). Referring to Table 2.4, we
can also see that state-months with operational PDMPs had a higher overall PORP rate
relative to states without PDMPs over the entire study period (1.621 vs. 1.180 per
100,000).
There was substantial variation in the overall PORP rate between states during
the study period. The heat map in Figure 2.5 displays the overall PORP rate from 2004 –
2014 in each state. The overall PORP rate ranged from a low of 0.630 per 100,000
person-months in DC to a high of 2.984 per 100,000 person-months in New Mexico.
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Figure 2.5 also indicates that states in the Western region of the United States generally
experienced the greatest overall PORP rates in this population.
Raw parameter estimates from the GEE Poisson regression model assessing the
association between PDMP implementation status and PORP rates are presented in
Table 2.5. In the adjusted model, states with operational PDMPs had significantly higher
PORP rates compared to states without PDMPs at baseline (p=0.0005). The estimated
adjusted regression coefficient for time was positive (β= 0.008), suggesting that the
PORP rate increased significantly over the study period (p < 0.0001). The regression
coefficient for the interaction between the indicator for ‘PDMP operational’ and time
was negative (β= -0.005) and statistically significant (<0.0001), suggesting that
operational PDMPs significantly mitigate the increases in PORP rate over time relative to
states without PDMPs. Western states were observed to have significantly higher PORP
rates relative to the rest of the US. Increasing rates of diagnosed SUD and a greater
proportion of the population being male were associated with significantly increased
PORP rates. The percentage of the population that were aged 25-35 years old was not
significantly associated with PORP rates.
Table 2.6 presents the exponentiated GEE parameter estimates from Table 2.9.
These may be interpreted as changes in the aRR of PORP associated with a one unit
change in the covariates of interest. For example, state-months experienced a
statistically significant increase in the RR of PORP of 1.028 [95% CI: 1.002 – 1.053] times
for every one percent increase in the percent of the population that was male. The
exponentiated form of the time effect variables may be used to understand how the
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aRR of PORP changes over time in states with and without PDMPs. States without
PDMPs experienced an average increase in aRR of PORP of 1.008 [95% CI: 1.005 – 1.01]
times from one month to the next over the study period. However, states with
operational PDMPs only experienced an average increase in aRR of PORP of 1.003 [95%
CI: 1.001 – 1.004] times from one month to the next. Because this 95% CI does not
overlap with the CI associated with aRR of PORP over time in states without PDMPs,
these results imply that states with operational PDMPs had significantly lower increases
in aRR of PORP over time relative to states without operational programs.
Adjusted RRs of PORP associated with one month increases in time for states
with different PDMP features are presented in a forest plot in Figure 2.6. In some
circumstances, states with operational PDMPs did not have significantly different
increases in aRR of PORP over time relative to states without PDMPs. Namely, states
with operational PDMPs that did not require unsolicited reporting, only required
monthly data reporting from pharmacies, or only monitored Schedule II or Schedule II-III
Controlled Substances did not have significantly different aRR of PORP over time relative
to states without PDMPs.
In all adjusted models, states without PDMPs and those that had passed PDMP
legislation but did not yet have operational programs, exhibited significant increases in
the aRR of PORP from one month to the next. In three of the four adjusted models
examining features of operational PDMPs, states with operational PDMPs that lacked
specific features had significant increases in aRR of PORP over time (and these increases
were not significantly different from those in states without PDMPs), but states with
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operational PDMPs that did have these features did not have significant changes in aRR
of PORP over time. For example, states with operational PDMPs that did not require
unsolicited reporting of PDMP data to prescribers or licensure boards experienced an
average increase in aRR of PORP of 1.003 times (95% CI: 1.001 – 1.005) from one month
to the next, while states with operational PDMPs that did require unsolicited reporting
in certain circumstances did not experience a significant change in aRR of PORP over
time (aRR: 1.001 [95% CI: 0.998 – 1.003]). Further, states with operational PDMPs that
required dispensers to upload dispensing data on a weekly or daily basis and those with
PDMPs that required prescribers to query the PDMP data in certain situations, did not
experience significant changes in aRR of PORP over time, but states with operational
PDMPs that lacked these features did have significant increases in aRR over time.
2.3.3 IORP Specific Results
From 2004 – 2014 there were a total of 10,822 distinct IORPs observed (Table
2.4). The overall rate of IORP from 2004 – 2014 was 0.403 per 100,000 person-months
observed. Figure 2.3 displays the overall IORP rate in each year from 2004 – 2014. There
was a statistically significant (p < 0.0001), 1,219% increase in the mean IORP rate over
the study period, from 0.076 per 100,000 person-months in 2004 to 1.008 per 100,000
person-months in 2014. The overall and mean IORP rates were calculated in the same
manner as for the overall and mean PORP rates. Figure 2.7 presents the trends in overall
annual IORP rates stratified by PDMP status. The figure shows that state-months with
operational PDMPs had nearly identical overall IORP rates in 2004 relative to states
without PDMPs (0.092 vs. 0.087 per 100,000 person-months). There was a consistent
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increase in overall IORP rates for all groups from 2004 – 2014, and in 2014 state-months
with operational PDMPs had a slightly higher overall IORP rate relative to states without
PDMPs (0.973 vs. 0.888 per 100,000 person-months).
There was substantial variation in the overall IORP rate between states during
the study period. The heat map in Figure 2.13 displays the overall IORP rate from 2004 –
2014 in each state. The overall IORP rate ranged from a low of 0 in Hawaii, where we did
not observe any IORPs over the study period, to a high of 1.030 per 100,000 personmonths in Massachusetts. Figure 2.13 also indicates that states in the Northeast and
Midwest regions of the United States generally experienced the greatest overall IORP
rates in this population.
Raw parameter estimates from the GEE Poisson regression model assessing
associations between PDMP implementation status and IORP rates are presented in
Table 2.7. In the fully adjusted model, states with PDMP legislation enacted without
operational programs, as well as states with operational PDMPs did not have
significantly different IORP rates relative to states without PDMPs at baseline (p = 0.266
and p = 0.497 respectively). The estimated regression coefficient for the time indicator
was positive and statistically significant (β= 0.0112, p= 0.0013), suggesting that the IORP
rate increased significantly over the study period. The coefficient for the interaction
between the indicator variable for ‘PDMP operational’ and time was positive and was
not statistically significant (β= 0.0025, p= 0.5103). This implies that states with
operational PDMPs also experienced increases in the IORP rate over the study period,
but these increases were not significantly different than those observed for states
58

without PDMPs. Midwestern states were seen to have significantly higher IORP rates
while Southern states had significantly lower IORP rates relative to states in the Western
region of the US. Increasing rates of diagnosed SUD and a greater percentage of the
population being male were associated with significantly increased IORP rates. The
percentage of the population that were aged 25-35 years old was not significantly
associated with IORP rates.
Table 2.8 presents the exponentiated GEE parameter estimates from Table 2.14.
These are interpreted as changes in the aRR of IORP associated with a one unit change
in the covariates shown. For example, state-months experienced an increase in the aRR
of IORP of 1.059 [95% CI: 1.002 – 1.120] times for every one percent increase in the
percent of the population that was male. As in the PORP specific results above, we can
use the exponentiated form of the time effect variables to understand how the aRR of
IORP changes over time in states with and without PDMPs. States without PDMPs
experienced an average increase in the aRR of IORP of 1.011 [95% CI: 1.004 – 1.018]
times from one month to the next over the study period. States with operational PDMPs
also experienced statistically significant increases in the aRR of IORP from one month to
the next (aRR: 1.014 [95% CI: 1.009 – 1.019]). These results indicate that states with
operational PDMPs experienced slightly greater increases in the aRR of IORP over the
study time period, however since the confidence intervals overlap substantially, we can
see that the increases were not significantly different.
Adjusted RRs of IORP associated with one month increases in time for states with
different PDMP features are presented in a forest plot in Figure 2.9. In four out of the
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five models, operational PDMPs—regardless of features present—do not have
significantly different increases in aRR of IORP over time relative to states without
PDMPs. The exception is the model investigating unsolicited reporting. States with
operational PDMPs that require unsolicited reporting experienced average increases in
aRR of IORP of 1.025 (95% CI: 1.020 – 1.030) times from one month to the next, while
states without PDMPs experienced average increases of 1.012 (95% CI: 1.004 – 1.018)
times from one month to the next. Because these CI’s do not overlap, we can see that
states with operational PDMPs that required unsolicited reporting experienced
significantly greater increases in aRR of IORP over time relative to states without
PDMPs. In the model investigating data reporting frequency, states with PDMPs that
required more frequent data reporting were trending towards having greater increases
in aRR of IORP over time, however, these increases were not significantly different from
those for states without PDMPs.
2.3.4 Sensitivity Analyses
Naloxone Access Laws
The number of states with naloxone access laws in place for the majority of the
year increased substantially during the study period, from 2 states in 2004 to 25 states
in 2014. Overall, there were 864 state-months with naloxone access laws in place from
2004 – 2014. Results of the sensitivity analysis revealed that naloxone access laws were
associated with reduced PORP rates in each of the GEE models examined, however,
none of these associations were statistically significant. P-values for the naloxone access
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law indicator variable ranged from 0.103 – 0.417 in the models investigating PORPs.
Furthermore, the presence of this variable did not attenuate associations between
PDMP features and trends in PORP rates over time in any of the models constructed. An
example of these results are presented in Table 2.9.
Results of the sensitivity analysis examining associations between naloxone
access laws and IORP rates revealed that naloxone access laws were significantly
associated with greater IORP rates in four of the five models constructed. Raw
parameter estimates from one of these models are presented in Table 2.10. Even
though these variables were significantly associated with IORP rates, including them in
the GEE models did not impact the significance of associations between PDMP features
and trends in IORP rates. For example, in the main analysis, states with operational
PDMPs that required proactive reporting were associated with significantly greater
increases in IORP rates over time relative to states with operational PDMPs that did not
require proactive reporting. This finding was also observed in the sensitivity analysis,
despite the parameter estimates for the interaction terms being slightly different than
those observed in the main analysis. The only model where naloxone access laws were
not associated with IORP rates was the model examining number of CS schedules
monitored, and here the naloxone access law indicator variable was trending towards
significance (p-vale 0.095).
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Buprenorphine Prescribing
The rate of buprenorphine use increased rapidly during the study period, from a
mean of 64.5 users per 100,000 beneficiaries in 2009 to 137.5 users per 100,000
beneficiaries in 2014. Greater rates of buprenorphine prescribing were generally
associated with higher PORP rates at the state month level however these associations
were not statistically significant. P-values for the buprenorphine prescribing rate
variable ranged from 0.052 – 0.217 in the GEE models constructed. Parameter estimates
for the interaction terms between PDMP features and the time indicator variable were
nearly equivalent in models including and not including the rate of buprenorphine use
as a covariate. Examples of these results are presented in Tables 2.11 and 2.12.
In models examining trends in IORPs, greater rates of buprenorphine use were
associated with significantly greater rates of IORPs. Despite these variables being
statistically significant, there were only negligible differences in parameter estimates for
the interaction terms between PDMP features and the time indicator variables in
models that did and did not include this covariate. These results may be seen in Tables
2.13 and 2.14. For example, in a model that did not include the rate of buprenorphine
prescribing as a covariate, states with operational PDMPs were associated with an
increase in IORP rates of 1.0158 times from one month to the next. However, In a model
that did include the rate of buprenorphine prescribing as a covariate, states with
operational PDMPs were associated with an increase in IORP rates of 1.0157 times from
one month to the next. Similar differences were seen in models investigating specific
PDMP features as well.
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2.4 Discussion
Over the last two decades, the number of operational PDMPs in the United
States has grown rapidly in response to the increasing intensity of the opioid epidemic.
In the privately insured adult population included in this study, rates of prescription and
illicit opioid-related poisonings both increased significantly from 2004 – 2014. While the
rates observed in this study are substantially different from those reported for the
population at large, the trends observed over this time period generally resemble those
reported by the CDC (comparing Figure 2.1 and Figure 2.3), which includes data for all
insurance types and age groups.
This study found that operational PDMPs, and specifically those with more
comprehensive or robust features, were associated with higher mean rates of PORP and
IORP relative to states without PDMPs. However, states that did not have operational
PDMPs experienced significant increases in the aRR of PORP over time during this study
period, while states with operational PDMPs with certain robust features did not
experience significant changes in the aRR of PORP over time. Contrarily, the results of
this study suggest that operational PDMPs had little effect on changes in the aRR of
IORP over time.Taken together these results suggest that operational PDMPs have
helped to mitigate the prescription opioid epidemic but have exerted little effect on
illicit opioid-related morbidity.
As seen in the CDC data presented in Figure 2.1, the prescription opioid epidemic
preceded the recent rise in IORPs. Further, PDMPs have historically been designed to
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address problems with prescription drug diversion and misuse. With this in mind, it is
plausible and in fact likely, that state legislatures initially implemented PDMPs and
further strengthened existing programs in response to relatively high rates of
prescription opioid-related morbidity and mortality occurring within their states. This
possibility is reflected in our finding that PDMPs with certain features are associated
with higher baseline RR of PORP. However, once implemented, operational PDMPs, and
specifically those with robust features such as sending unsolicited reports and requiring
more frequent reporting from dispensers, exert a protective effect on at-risk
populations moving forward. While this framework may not fit each state individually, it
reflects the population-average results.
There are several plausible mechanisms by which PDMPs may reduce the supply
of prescription opioids analgesics and thus reduce the risk of PORP in the privatelyinsured adult population. Prescribers may utilize PDMP data at the point of care,
allowing them to identify patients with multiple provider episodes or potentially
inappropriate overlapping prescriptions of other CS (i.e. benzodiazepines, muscle
relaxants etc.). One previous study found that most prescribers surveyed indicated that
accessing PDMP data altered their CS prescribing.134 PDMPs may also assist professional
licensure boards and law enforcement officials in identifying and potentially prosecuting
prescribers with aberrant CS prescribing. The current study does not fully elucidate the
mechanism by which PDMPs may reduce opioid-related morbidity. However, we did find
that states with operational PDMPs that send unsolicited reports to professional
licensure boards or prescribers, as well as those that require prescribers to query the
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PDMP data in certain situations avoided significant increases in the aRR of PORP over
time.
Some researchers and pundits have pointed to PDMPs—along with other system
level interventions attempting to reduce overall supply of prescription opioids—as a
potential catalyst for the increases in IORPs observed in recent years.102-106
Theoretically, by making it more difficult to obtain prescription opioids, individuals
suffering from drug addiction are forced to substitute prescription drugs for illicit
opioids such as heroin. If PDMPs were driving this substitution, our results would have
indicated that operational PDMPs were associated with significantly greater increases in
aRR of IORP over time relative to states without PDMPs. In actuality, we observed little
differences in changes in aRR of IORP over time between states with and without
operational PDMPs.
Although this substitution theory did not clearly play out in our data, there are
several reasons why it may still be true despite our failure to observe it in this
population. First, it may be that this type of substitution is more prominent in the
Medicaid or uninsured populations relative to the privately insured. Descriptive results
from this study show that the privately insured are substantially less prone to IORPs
relative to PORPs (Table 2.4). Second, it may be that the substitution is engendered by
other opioid-related policies not investigated in this study, such as crackdowns on pill
mills in certain states, or the release of abuse deterrent oxycodone. Finally, it may be
that the time frame included in this study is not recent enough to adequately capture
the phenomenon. Theoretically, this type of substitution would be a downstream effect
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of robust PDMP policies that were just beginning to increase in popularity towards the
end of the study period.
Presently, every state except for Missouri has an operational PDMP, however,
the results of this study may be used as evidence to support the adoption of several key
features. As in previous studies, these results indicate that PDMPs should strive to
monitor all CS Schedules and should require dispensers to report prescription data on a
daily or at least weekly basis. Results of this study also show that operational PDMPs
that lack specific features, specifically mandatory querying or unsolicited reporting, are
associated with significant increases in the aRR of PORP over time. In contrast,
significant changes in aRR of PORP over time were not observed in states with
operational programs that have implemented these features. These findings should be
used by state policymakers to support the adoption of progressive PDMP features, and
should also quell concerns that robust PDMPs are pushing individuals to use illicit
opioids.
The main results of this study still held upon completion of two robust sensitivity
analyses. In the first, GEE models were re-fit including an indicator variable for naloxone
access laws. Results of this sensitivity analysis indicated that naloxone access laws were
not significantly associated with PORP rates at the state level, nor did they impact
observed associations between PDMP features and trends in PORP rates over time. On
the other hand, these laws were observed to be significantly associated with greater
IORP rates. However, again it was seen that including this variable in the adjusted GEE
models did not lead to substantial changes in the observed associations between PDMP
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features and trends in IORP rates. It is not immediately clear why naloxone access laws
were observed to be significantly associated with higher IORP rates but were not
significantly associated with PORP rates. It may be that states with the highest IORP
rates reactively implement naloxone access laws, or use of naloxone may allow more
individuals to survive initial IORPs and eventually be seen in the ED.
The second sensitivity analysis sought to examine whether trends in
buprenorphine prescribing impacted observed associations between PDMP features
and trends in rates of PORPs and IORPs. Results indicated that state-month rates of
buprenorphine prescribing were not significantly associated with PORP rates, and
associations between PDMP features and trends in PORP rates were nearly equivalent in
models that did and did not include buprenorphine prescribing as a covariate. In models
examining rates of IORPs, it was observed that greater rates of buprenorphine
prescribing were generally associated with significantly higher IORP rates. Despite this
statistical significance though, associations between PDMP features and trends IORP
rates over time were not substantially different in models that did and did not include
buprenorphine prescribing as a covariate.
This study addressed several important gaps in the PDMP literature. First, even
though it is well known that PDMPs exhibit variability among states, most studies
investigating the impact of PDMPs on prescription opioid-related morbidity and
mortality do not address program heterogeneity. Two recent studies investigating
specific PDMP features found that PDMPs that monitor more schedules, require more
frequent data reporting from dispensers, and have a greater number of robust features,
67

are associated with significantly lower rates of opioid-related mortality.42,90 The current
study used rigorous feature attribution and statistical methods to both confirm and
expand on the results of these studies. In addition to the two aforementioned features,
our study also highlights the importance of PDMPs sending unsolicited reports and
requiring mandatory data querying prior to controlled substance prescribing.
Additionally, our study developed separate statistical models for each PDMP feature of
interest to provide greater granularity in terms of the effects of individual program
elements and, thus, offers further evidence to guide PDMP best-practices.
This study is also the first to our knowledge to specifically assess differential
effects of PDMPs on prescription vs. illicit opioid-related poisonings. The findings of this
study suggest that PDMPs offer a useful tool in addressing increasing rates of PORP but
that they have had little impact on burgeoning rates of IORP in recent years. This implies
that in order to address recent increases in IORPs, additional system level interventions
are needed, or PDMPs need to implement some novel functionality that goes beyond
their historical function of solely monitoring CS prescribing. The existing PDMP
infrastructure could serve as a useful starting point for innovations to help providers
identify persons with SUD and assist them in obtaining treatment. PDMP data could be
integrated with other data sources such as medical records or arrest records to identify
persons at high risk of IORP or PORP and allow providers to intervene at an early stage.
Finally, this study was the first to examine associations between PDMP
implementation and rates of PORP and IORP specifically in a population of privately
insured adults. Given that this is a generally healthy and employed population, the
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overall rates of PORP and IORP observed in this study were substantially lower than
annual rates reported by the CDC. Despite the relatively low rates in this population, it is
still of interest for several reasons. Research suggests that the current opioid epidemic
disproportionately impacts middle-class individuals relative to previous crises which
have predominantly impacted the Medicaid population and minority groups.98,135,136 A
recent study of opioid-related hospital admissions from 1993 - 2012 found a greater
rate of increase in the privately-insured population than in the Medicaid or uninsured
populations 137. Finally, as health care based programs, it is plausible that PDMPs may
have a differential impact on the privately insured population than on the American
public at large. If so, this might explain why previous studies, relying on data from all
payer groups, have failed to find significant associations between PDMP implementation
and trends in opioid-related mortality.
2.5 Limitations
Despite the strengths of this study, it was subject to several notable limitations.
Most importantly, the administrative claims data used in this study are generated for
reimbursement—not research—purposes and are prone to diagnosis misclassification.
In particular, ICD-9-CM codes related to drug poisonings suffer from poor sensitivity due
to limited utilization of drug screenings in healthcare settings. 138,139 A recent study by
Rowe et al. found that the ICD-9-CM codes used in this study identified opioid-related
poisoning ED visits with a sensitivity of 25% and a specificity of 99.9%.139 Importantly,
this study did not differentiate the sensitivity and specificity for codes related to
prescription vs. illicit opioid-related poisonings. Given this poor sensitivity and high
69

specificity, the aRR estimates found in this study are likely substantially below their true
values.140 Although this impacts the magnitude of the aRR estimates found in this study,
the results of this study are still valuable in terms of understanding the relative
contribution of PDMP features. Take for example the model investigating associations
between data reporting frequency and changes in the aRR of PORP over time. Even
though each of these aRRs is likely underestimated, it still holds that weekly and daily
data reporting are associated with protective effects on the aRR of PORP over time
relative to monthly data reporting—regardless of what the actual magnitudes of those
effects are.
In addition to the poor sensitivity of opioid-related poisoning codes in general, it
may also be difficult to differentiate PORPs from IORPs in the absence of drug screening
data. Previous studies have found that drug screenings take place in only about 40% of
ED visits for drug related poisonings.141,142 This is particularly problematic considering
the recent rise of illicitly manufactured fentanyl. Although fentanyl is technically a
prescription opioid, many of the fentanyl poisoning cases encountered today are due to
fentanyl manufactured in China and shipped to the United States to be sold as heroin.96
Presumably, in the absence of drug screenings, ED physicians will ask patients what
substances may have led to their suffering an acute poisoning. Even if patients are
forthcoming with this information, it is unlikely that they will know whether their
‘heroin’ was in fact fentanyl mixed with other substances. Ideally, fentanyl poisonings
would be examined separately from other ‘licit’ opioid-related poisonings, but the ICD9-CM codes used in this study are not able to distinguish fentanyl poisonings from other
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types of PORPs. Fortunately for this study though, rates of fentanyl-related poisonings
did not begin increasing rapidly until about 2014 (as seen in Figure 2.1), which was the
last year of the study period. Further complicating this issue is the fact that heroin is
metabolized into morphine.141 Thus even when drug screenings are used, they may
misidentify heroin related poisonings if they are applied long after the poisoning event.
This study also suffered from several other data limitations in addition to the
weaknesses related to the opioid-related poisoning codes. The administrative claims
data used in this study are also lacking several demographic measures of interest,
including the racial/ethnic makeup and socioeconomic status of the study population.
The two datasets used to characterize the timing of PDMP legislation enactment and
operation were inconsistent at times. However, by using two datasets we were able to
conservatively define dates of program enactment and operation and thus mitigate the
chances of misclassification which may have impacted the results of previous studies of
PDMPs 92.
Finally, the ‘natural experiment’ design utilized in this study is only capable of
demonstrating associations and cannot be used to make inferences about causality 112.
This is a particularly salient point considering that additional interventions such as
expanded access to naloxone, the release of abuse deterrent opioid formulations, and
other state specific policy changes may have impacted trends in opioid-related
morbidity during the study time period. Using a natural experiment approach, it is
difficult to disentangle the effects of these interventions from that associated with
implementation of PDMPs. Although these additional interventions may bias the
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parameter estimates observed in this study, the results are still valid in terms of
demonstrating the relative impacts of different PDMP features on trends in opioidrelated morbidity. Put differently, even if these results overestimate the impact of
PDMPs in general, they still offer valuable evidence to suggest that PDMPs with certain
features are better able to mitigate trends in PORPs relative to PDMPs without these
features.
2.6 Conclusion
Results of this study showed that privately-insured adults residing in states with
operational PDMPs were, on one hand, exposed to higher baseline risk of PORP, but, on
the other, more protected from increases in PORP risk during a period of intensification
of the opioid epidemic. Conversely, adults residing in states with PDMPs were not seen
to have significantly different trends in IORP risk relative to adults in states without
PDMPs. Specific PDMP features, including requiring unsolicited reporting to prescribers,
law enforcement, or professional licensure boards, more frequent data reporting by
dispensers, and monitoring more CS Schedules, were associated with stronger
protective effects on PORP risk over time compared to states with operational programs
that lack these features. However, these features did not appear to impact trends in
IORP risk. These results may be used to improve the efficacy of current and future
PDMPs which are proliferating worldwide. Future research is necessary to assess
whether these features are also associated with opioid prescribing, and other measures
of prescription opioid misuse. Finally, in order to have the greatest impact on the opioid
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epidemic in the United States, PDMPs may need to innovate to help health care
providers rapidly identify individuals who may be in need of SUD treatment.
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Figure 2.1: Overdose deaths involving opioids, by type of opioid, United States 2000 –
2016 143
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Table 2.1: Prescription and illicit opioid-related poisonings ICD-9-CM Codes
Type of diagnosis
Prescription opioid-related poisoning
Illicit opioid-related poisoning

ICD-9-CM Codes
965.00, 965.02, 965.09, E850.1, E850.2
965.01, E850.0

Table 2.2: Coding scheme for PDMP features of interest
Variable
Status of the PDMP

Levels
0= No PDMP
1= PDMP legislation enacted only
2= PDMP operational
Is the PDMP required to send proactive
0= No PDMP
reports to any entities?
1= PDMP legislation enacted only
2= No
3= Yes
How often are pharmacies required to
0= No PDMP
upload data to the PDMP?
1= PDMP legislation enacted only
2= Monthly or less often
3= Weekly
4= Daily
What Schedules is the PDMP required to 0= No PDMP
monitor?
1= PDMP legislation enacted only
2= II Only, or II – III
3= II – IV
4= II – V
Are prescribers required to query the
0= No PDMP
PDMP data in certain situations?
1= PDMP legislation enacted only
2= No
3= Yes
Acronyms: PDMP- Prescription Drug Monitoring Program
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Figure 2.2: Visualization of PDMP operational dates and implementation of unsolicited
reporting requirements

Acronyms: PDMP- Prescription Drug Monitoring Program
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Table 2.3: Number of states with different PDMP features in place at the end of each
year
No PDMP
PDMP
Legislation
Passed
PDMP
operational

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
29
27
22
16
13
12
8
3
3
2
1
8
9
12
12
11
6
9
13
7
4
2

13

14

16

22

26

32

33

34

40

44

47

14
2
0

20
2
0

21
5
0

24
8
0

21
11
1

18
15
1

14
24
2

12
28
4

9
28
10

The PDMP is required to send unsolicited reports to certain entities
No
11
10
11
17
19
22
22
21
Yes
2
4
5
5
7
10
11
13

25
15

27
17

29
18

Data reporting frequency
Monthly
11
12
Weekly
2
2
Daily
0
0

Drug schedules required to be reported to the PDMP
II only or
4
4
4
4
4
4
II-III
II – IV
1
2
2
2
2
4
II – V
8
8
10
16
20
24

2

1

0

0

0

5
26

5
28

5
35

5
39

5
42

Prescribers are Required to query the PDMP in certain situations
No
13
14
16
22
26
32
33
34
Yes
0
0
0
0
0
0
0
0
Acronyms: PDMP- Prescription Drug Monitoring Program

39
1

41
3

41
6
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Table 2.4: Characteristics of state-months with and without operational PDMPs
No PDMP

PDMP
Enacted
1,111
507,559,090
7,112
1.401
1.306
1,934
0.381
0.294
102.58
48.0%

PDMP
operational
3,858
1,798,838,473
29,161
1.621
1.650
8,256
0.459
0.414
151.66
48.1%

Overall

State-months
1,631
6,600
Person-months
380,773,381
2,687,170,944
Number of PORPs
4,493
40,766
Overall PORP rate
1.180
1.517
Mean PORP rate
1.128
1.463
Number of IORPs
632
10,822
Overall IORP rate
0.166
0.403
Mean IORP rate
0.145
0.328
Average SUD rate
66.78
122.42
Mean percent
47.3%
47.9%
male
Mean percent
21.7%
19.9%
20.6%
20.8%
aged 25-35
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioidrelated poisoning; IORP- Illicit opioid-related poisoning; SUD- Substance use disorder
*Rates expressed per 100,000 person-months
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Figure 2.3: Overall PORP and IORP rates per 100,000 person-months observed in each
year 2004 – 2014

Overall Rates of PORP and IORP
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IORP Rate

Acronyms: PORP- prescription opioid-related poisoning; IORP- illicit opioid-related
poisoning

Figure 2.4: Overall PORP rates per 100,000 person-months observed in each year
stratified by PDMP status

Overall PORP Rates by PDMP Status
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Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioidrelated poisoning
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Figure 2.5: Overall rate of PORP per 100,000 person-months in each state form 2004 –
2014

Acronyms: PORP- prescription opioid-related poisoning
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Table 2.5: GEE parameter estimates for model examining associations between PDMP
status and PORP rates
Variable

GEE
Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

0.124
0.451

0.5951
0.0005

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

-0.046
0.288

Ref.
0.087
-0.216
0.083
0.126

Time Effect
Month
PDMP Enacted*Month
PDMP Operational*Month

0.008
-0.001
-0.005

0.001
0.001
0.001

0.005
-0.003
-0.008

0.01
0.002
-0.003

<.0001
0.6847
<.0001

-0.237
-0.316
-0.167

Ref.
0.109
-0.450
0.098
-0.509
0.077
-0.318

-0.024
-0.124
-0.016

0.0290
0.0013
0.0304

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
0.027
0.013
0.002
0.052 0.0337
% of population aged 25-35
-0.006
0.010
-0.026
0.014 0.5464
CCS SUD Rate
0.002
0.0004
0.001
0.002 0.0004
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioidrelated poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder
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Table 2.6: Adjusted relative risk of PORP in model investigating PDMP status
Variable

Adjusted Relative
Risk

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

0.9551
1.3342

Ref.
0.8061
1.1345

1.1315
1.5691

0.5951
0.0005

Time Effect
Month
PDMP Enacted*Month
PDMP Operational*Month

1.0076
1.0071
1.0026

1.0054
1.0053
1.0010

1.0099
1.0089
1.0042

<.0001
<.0001
0.0011

0.7888
0.7290
0.8461

Ref.
0.6375
0.6012
0.7273

0.9761
0.8838
0.9843

0.0290
0.0013
0.0304

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
1.0275
1.0021
1.0536
0.0337
% of population aged 25-35
0.9939
0.9742
1.0139
0.5464
CCS SUD Rate
1.0015
1.0007
1.0024
0.0004
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioidrelated poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder
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Figure 2.6: Forest plot displaying changes in aRR of PORP from one month to the next
associated with each PDMP feature of interest

Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioidrelated poisoning; aRR- adjusted relative risk; LCL- lower confidence limit; UCL- upper
confidence limit

83

Figure 2.7: Overall IORP rate per 100,000 person-months in each year by PDMP status
2004 – 2014

Overall IORP Rates by PDMP Status
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Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related
poisoning;
Figure 2.8: Overall rate of IORP per 100,000 person-months in each state from 2004 –
2014
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Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related
poisoning;
Table 2.7: GEE parameter estimates for model examining associations between PDMP
status and IORP rates
Variable

GEE
Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

0.4511
0.4842

0.2666
0.4969

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

-0.5903
-0.2569

Ref.
0.5314
-1.6318
0.3781
-0.9979

Time Effect
Month
PDMP Enacted*month
PDMP Operational*month

0.0112
0.0080
0.0025

0.0035
0.0052
0.0037

0.0044
-0.0021
-0.0049

0.0181
0.0182
0.0098

0.0013
0.1219
0.5103

0.6788
0.3364
-0.3483

Ref.
0.1763
0.3332
0.1903
-0.0365
0.1602
-0.6623

1.0244
0.7093
-0.0344

0.0001
0.0770
0.0297

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
0.0576
0.0286
0.0016
0.1137 0.0438
% of population aged 25-35
-0.0221
0.0259
-0.0729 0.0288 0.3950
CCS SUD Rate
0.0051
0.0007
0.0037
0.0065 <.0001
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related
poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder
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Table 2.8: Adjusted relative risk of IORP in model investigating PDMP status
Variable

Adjusted Relative
Risk

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

0.5541
0.7735

Ref.
0.1956
0.3687

1.5701
1.6228

0.2666
0.4969

Time Effect
Month
PDMP Enacted*Month
PDMP Operational*Month

1.0113
1.0195
1.0138

1.0044
1.0113
1.0091

1.0183
1.0276
1.0185

0.0013
<.0001
<.0001

1.9716
1.3999
0.7059

Ref.
1.3954
0.9642
0.5157

2.7855
2.0326
0.9662

0.0001
0.0770
0.0297

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
1.0593
1.0016
1.1204
0.0438
% of population aged 25-35
0.9782
0.9297
1.0292
0.3950
CCS SUD Rate
1.0051
1.0037
1.0065
<.0001
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related
poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder
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Figure 2.9: Forest plot displaying changes in aRR of IORP from one month to the next
associated with each PDMP feature of interest

Acronyms: PDMP- prescription drug monitoring program; IORP- Illicit opioid-related
poisoning; aRR- adjusted relative risk; LCL- lower confidence limit; UCL- upper
confidence limit
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Table 2.9: GEE parameter estimates for model examining associations between PDMP
status and PORP rates, controlling for Naloxone access laws
Variable

GEE
Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

-0.0433

0.0872

-0.2142

0.1276

0.6195

PDMP Operational

0.2715

0.0869

0.1012

0.4418

0.0018

Time Effect
Month

0.0075

0.0011

0.0053

0.0097

<.0001

PDMP Enacted*Month

-0.0007

0.0014

-0.0034

0.0020

0.6060

PDMP Operational*Month

-0.0046

0.0013

-0.0072

-0.0020

0.0006

Ref.

Region
West
Midwest

-0.2356

0.1083

-0.4478

-0.0234

0.0295

Northeast

-0.2868

0.1128

-0.5079

-0.0658

0.0110

South

-0.1766

0.0800

-0.3334

-0.0199

0.0272

Ref.

Naloxone Access Law in Place?
No

Ref.

Yes

-0.0929

0.0825

-0.2546

0.0688

0.2602

Continuous Variables
% male population

0.0259

0.0131

0.0003

0.0516

0.0477

% of population aged 25-35

-0.0053

0.0103

-0.0256

0.0150

0.6090

CCS SUD Rate

0.0016

0.0004

0.0008

0.0024

0.0001

Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioidrelated poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder
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Table 2.10: GEE parameter estimates for model examining associations between
PDMP status and IORP rates, controlling for Naloxone access laws
Variable

GEE
Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

-0.6250

0.5519

-1.7067

0.4567

0.2574

PDMP Operational

-0.2069

0.3724

-0.9367

0.5230

0.5786

Time Effect
Month

0.0116

0.0035

0.0048

0.0185

0.0009

PDMP Enacted*Month

0.0088

0.0054

-0.0017

0.0194

0.1011

PDMP Operational*Month

0.0013

0.0037

-0.0060

0.0085

0.7342

Ref.

Region
West

Ref.

Midwest

0.6739

0.1519

0.3762

0.9716

<.0001

Northeast

0.2615

0.2032

-0.1367

0.6597

0.1981

South

-0.3197

0.1423

-0.5986

-0.0409

0.0246

Naloxone Access Law in Place?
No

Ref.

Yes

0.2106

0.0995

0.0156

0.4057

0.0343

Continuous Variables
% male population

0.0619

0.0286

0.0059

0.1180

0.0304

% of population aged 25-35

-0.0281

0.0269

-0.0808

0.0247

0.2971

CCS SUD Rate

0.0049

0.0007

0.0036

0.0062

<.0001

Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related
poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder
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Table 2.11: GEE parameter estimates for model examining associations between
PDMP status and PORP rates from 2009 – 2014
Variable

GEE
Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

-0.1489

0.2972

-0.7313

0.4336

0.6164

PDMP Operational

0.1425

0.2493

-0.3462

0.6312

0.5678

Time Effect
Month

-0.0004

0.0027

-0.0058

0.0050

0.8921

PDMP Enacted*Month

0.0011

0.0032

-0.0051

0.0073

0.7177

PDMP Operational*Month

-0.0025

0.0028

-0.0080

0.0030

0.3697

Ref.

Region
West
Midwest

-0.1863

0.1236

-0.4286

0.0559

0.1317

Northeast

-0.2425

0.1031

-0.4446

-0.0404

0.0187

South

-0.1255

0.0807

-0.2836

0.0327

0.1200

Continuous Variables
% male population

0.0326

0.0139

0.0053

0.0598

0.0192

% of population aged 25-35

-0.0033

0.0127

-0.0283

0.0217

0.7956

CCS SUD Rate

0.0016

0.0005

0.0006

0.0027

0.0021

Ref.

Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioidrelated poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder
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Table 2.12: GEE parameter estimates for model examining associations between
PDMP status and PORP rates from 2009 – 2014, controlling for rates of buprenorphine
prescribing
Variable

GEE
Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

-0.1890

0.2938

-0.7648

0.3868

0.5200

PDMP Operational

0.1230

0.2444

-0.3561

0.6021

0.6147

Time Effect
Month

-0.0006

0.0027

-0.0059

0.0046

0.8132

PDMP Enacted*Month

0.0015

0.0031

-0.0047

0.0076

0.6360

PDMP Operational*Month

-0.0023

0.0027

-0.0077

0.0030

0.3961

Ref.

Region
West

Ref.

Midwest

-0.2245

0.1114

-0.4429

-0.0061

0.0439

Northeast

-0.2769

0.0996

-0.4721

-0.0817

0.0054

South

-0.2079

0.0794

-0.3635

-0.0524

0.0088

Continuous Variables
% male population

0.0246

0.0146

-0.0040

0.0531

0.0914

% of population aged 25-35

0.0001

0.0120

-0.0235

0.0237

0.9930

CCS SUD Rate

0.0008

0.0007

-0.0005

0.0021

0.2141

Buprenorphine Rx rate

0.0012
0.0006
-0.0000 0.0023 0.0518
Acronyms: PDMP- Prescription Drug Monitoring Program; PORP- prescription opioidrelated poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder; Rxprescription
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Table 2.13: GEE parameter estimates for model examining associations between
PDMP status and IORP rates from 2009 – 2014
Variable

GEE
Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

-0.4354

0.6983

-1.8041

0.9333

0.5330

PDMP Operational

-0.4970

0.5860

-1.6455

0.6515

0.3963

Time Effect
Month

0.0113

0.0052

0.0012

0.0214

0.0282

PDMP Enacted*Month

0.0067

0.0064

-0.0059

0.0192

0.2959

PDMP Operational*Month

0.0043

0.0051

-0.0057

0.0143

0.3999

Ref.

Region
West

Ref.

Midwest

0.7498

0.1666

0.4233

1.0763

<.0001

Northeast

0.3077

0.1703

-0.0261

0.6416

0.0708

South

-0.3310

0.1434

-0.6120

-0.0499

0.0210

Continuous Variables
% male population

0.0567

0.0337

-0.0095

0.1228

0.0930

% of population aged 25-35

-0.0157

0.0260

-0.0667

0.0354

0.5475

CCS SUD Rate

0.0051

0.0006

0.0040

0.0063

<.0001

Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related
poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder
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Table 2.14: GEE parameter estimates for model examining associations between
PDMP status and IORP rates from 2009 – 2014, controlling for rates of buprenorphine
prescribing
Variable

GEE
Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

-0.5197

0.6702

-1.8333

0.7939

0.4381

PDMP Operational

-0.5975

0.5613

-1.6976

0.5026

0.2871

Time Effect
Month

0.0102

0.0049

0.0006

0.0198

0.0374

PDMP Enacted*Month

0.0074

0.0061

-0.0046

0.0194

0.2265

PDMP Operational*Month

0.0054

0.0048

-0.0041

0.0148

0.2654

Ref.

Region
West

Ref.

Midwest

0.6766

0.1540

0.3749

0.9784

<.0001

Northeast

0.2470

0.1483

-0.0437

0.5377

0.0959

South

-0.5504

0.1466

-0.8377

-0.2630

0.0002

Continuous Variables
% male population

0.0261

0.0363

-0.0452

0.0973

0.4733

% of population aged 25-35

0.0011

0.0246

-0.0472

0.0493

0.9645

CCS SUD Rate

0.0035

0.0008

0.0020

0.0050

<.0001

Buprenorphine Rx rate

0.0028
0.0009
0.0010
0.0046 0.0018
Acronyms: PDMP- Prescription Drug Monitoring Program; IORP- illicit opioid-related
poisoning; GEE- generalized estimating equation; CI- confidence interval; RefReference; CCS- clinical classification software; SUD- substance use disorder; Rxprescription
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Chapter 3: Examining Differential Associations Between PDMP Features and Trends In
Prescription Opioid-Related Poisonings In Populations With Different Types of
Insurance Coverage
3.1 Introduction
In order to efficiently and effectively address the US opioid epidemic, it is critical
that policy makers and researchers understand where the epidemic is exerting the
greatest effects. With the passage of the 21st Century Cures Act, the federal government
is making available substantial funding to promote both prevention and treatment
related to opioid addiction.144 In order for these resources to be deployed effectively,
we must understand what groups are most in need. For patients with public or private
insurance, many interventions related to both prevention and treatment of opioid
addiction require engagement with the existing health insurance infrastructure.
Alternatively, uninsured or underinsured individuals will need access to federally
subsidized or charitable treatment services. To adequately address the needs of these
diverse populations, it is imperative that we understand where resources should be
directed to have the most impact.
Unfortunately, very little reliable data exists regarding the burden of opioid
addiction and substance use disorder (SUD) among populations with different types of
insurance coverage. The CDC regularly prepares reports on trends in both prescription
and illicit opioid-related mortality.145 These data are aggregated from cause of death
reports and contain basic demographic information related to age, gender, race etc. The
CDC often reports trends in mortality stratified by these demographic characteristics,
however, they lack information related to insurance status of the deceased. Without
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this type of aggregate data, it is impossible to ascertain how opioid-related mortality
varies among individuals with different types of insurance.
There have been several previous studies assessing potential opioid misuse and
multiple provider episodes by individuals with different types of insurance. Sullivan et al.
developed a numeric score to define the potential for opioid misuse in a population of
commercially insured individuals and Medicaid recipients.146 In a population of patients
receiving chronic opioid therapy, they found that 24% of the privately insured and 20%
of the Medicaid patients met their criteria for possible opioid misuse, and 6% of the
privately insured and 3% of the Medicaid patients met their criteria for probable opioid
misuse.146 A 2017 report from the Office of the Inspector General found that about
22,000 Medicare beneficiaries nationwide appeared to be doctor shopping for opioids in
2015.147 In contrast, a 2009 report from the Government Accountability Office found
that more than 65,000 Medicaid beneficiaries in a five state sample engaged in doctor
shopping during fiscal years 2006 and 2007.148 Although The GAO report is outdated
and doesn’t differentiate between opioids and other CS, these results still seem to imply
that doctor shopping for opioids is likely to be substantially more common in the
Medicaid population as a whole.
Several studies examining demographic characteristics associated with
prescription opioid-related morbidity offer some evidence of variation by insurance
status. A 2015 study using data from the National Emergency Department Sample
(NEDS) found that the Medicare population had significantly more unintentional PORPs
from 2006 – 2011 relative to all other insurance types.149 This same study found that the
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privately insured population had significantly more intentional PORPs relative to all
other insurance types over the same time period.149 An earlier study from Hasegawa et
al. examined two years of emergency department data from Florida and California and
found that privately insured, Medicare, and uninsured patients each accounted for
equal proportions of all opioid-related ED visits.150 This study may have found different
results than the NEDS study because it failed to differentiate prescription and illicit
opioid-related ED visits. A prominent limitation to both of these studies, however, is
that they only examine counts and not rates of opioid-related poisonings. By only
presenting counts of poisonings attributable to each insurance type, it is difficult to
assess whether one group is experiencing disproportionally more or less opioid-related
morbidity than the others.
Prescription drug monitoring programs (PDMPs) have been widely implemented
as a tool to reduce prescription opioid-related morbidity and mortality. Presently, 49
states and the District of Columbia have operational PDMPs.151 Although there is a
tremendous amount of research examining the impact of PDMPs on both opioid
prescribing as well as opioid-related morbidity and mortality, no studies, to date, have
examined whether these programs exert differential effects on individuals with different
types of health insurance. As healthcare based programs that operate at the point-ofcare, it is plausible that PDMPs may have different effects on patients with and without
insurance, or with different types of insurance. In this sense, type of insurance coverage
may impart differential associations between PDMP implementation and trends in
opioid-related morbidity. Also, it remains to be seen whether specific features of
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operational PDMPs are more or less successful at reducing opioid-related morbidity in
patients with certain types of insurance coverage.
To date, all studies examining associations between PDMP implementation and
trends in prescription opioid-related mortality have done so using the CDC WONDER
data or state specific mortality data which do not include data on insurance status of the
deceased.42,67,88,90,91 Two previous studies assessing associations between PDMP
implementation and trends in nonfatal PORPs were conducted using DAWN and
RADARS data which also do not include data on patients’ insurance status.82,83 In 2016,
Meara et al. conducted a study using Medicare claims data to explore associations
between PDMPs and PORP-related ED visits in a population of disabled Medicare
beneficiaries—this was the first and only study to date to examine the effects of PDMPs
in a population where the patients’ insurance status was known to the researchers.85
Meara et al. found that individuals residing in PDMP states did not have significantly
different odds of experiencing a PORP relative to patients in non-PDMP states.85 The
study presented in Chapter 2 of this dissertation found that states with operational
PDMPs were associated with significantly lower increases in PORP rates over time
relative to states without PDMPs. Taken together, these two studies indicate that
insurance status may impart differential associations between PDMPs and nonfatal
PORPs in populations with different types of coverage.
This study will address several important gaps in the existing literature
examining the opioid epidemic and PDMPs. This study will be the largest study to date
to assess trends In PORP rates among populations with different types of insurance, and
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will also be the first to examine differential associations between PDMP implementation
and trends in PORPs in populations with different types of insurance coverage. The
specific aims of this study are to: I. Describe trends in PORP-related hospital discharges
in the privately insured, Medicaid, Medicare, and uninsured populations; II. Examine
differential associations between PDMP implementation and trends in PORPs in
populations with different types of insurance coverage; and III. Assess whether there
are also differential associations between specific PDMP features and trends in PORPs in
populations with different types of insurance coverage
3.2 Methods
3.2.1 Study Design
This analysis employed an observational longitudinal, ‘natural experiment’
design to assess associations between PDMP features and rates of PORPs in populations
with different insurance status. Natural experiments are empirical studies wherein
subjects are exposed to an intervention that is outside the control of the investigator. 112
This study included a sample of 16 states and included observations for every county in
each of those states. Changes to PDMP features—including timing of initial legislation
enactment and program implementation, or alterations to specific functionality—were
assessed annually in the 16 state study sample from 2001 – 2014. The unit of
observation was the county-year-plan type (i.e. there was one observation per county,
per year, per insurance plan type of interest). This assessed four distinct insurance plan
types—private insurance, Medicaid, Medicare, and uninsured status. The outcome of
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interest in this study was the number of PORPs observed in hospital discharge data in
each county-year-plan type set from 2001 – 2014. The relative risk of PORP was
calculated for each county-year-plan type set during this period while controlling for
specific PDMP features as well as demographic and clinical characteristics of the study
population observed at the county-year-plan type, or county-year level (in cases where
plan type specific data was unavailable). Given that this study was observational and
relied on de-identified data collected for research purposes, it was deemed exempt
from review by the University of Kentucky IRB.
3.2.2 Data
This study utilized data from multiple sources. Data regarding clinical events as
well as clinical and some demographic characteristics of the privately insured, Medicaid,
Medicare, and uninsured population were obtained from the Healthcare Cost and
Utilization Project (HCUP) State Inpatient Databases (SID). The HCUP SID data include
inpatient discharge records from community hospitals in 48 participating states. This
study utilized a sample of 16 states from 2001 – 2014. Table 3.1 details the specific
states included in this analysis and the time period during which each states’ data were
available. Most states were observed for the entire study time period from 2001 – 2014,
however, 4 of the 16 states had limited years of data available. These 16 states were
chosen in conjunction with this time period as it allowed most states to be observed
both before and after their PDMPs became operational.
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HCUP SID data are translated into a uniform format to allow multi-state
comparisons and analyses. The SID data encompass approximately 97% of all US
community hospital discharges in participating states.152 Data elements collected at
discharge include diagnoses observed during the hospital stay, demographic
characteristics including age, gender, and race, and primary expected payer for the
hospital admission. These data are unique in that they encompass hospital stays from all
payer types, including individuals covered by Medicare, Medicaid, private insurance, and
individuals who are uninsured. All hospital discharges observed in the 16 state sample
during the years of data available for each state were included in the analysis. Individual
discharges were aggregated into rates and percentages at the county-year-plan type
level.
Several demographic characteristics of interest including the mean
unemployment rate and poverty rate in each county were assessed using external data
sources. The Bureau of Labor Statistics’ Local Area Unemployment data were used to
assess the annual unemployment rate in each county in the 16 states of interest from
2001 – 2014.153 The US Census Bureau’s Small Area Income and Poverty Estimates data
were used to assess the annual poverty rate in each county in the 16 state sample from
2001 – 2014.154 These data could not be examined by insurance status, and so were
assessed only at the county-year level rather than the county-year-plan type level.
Data regarding the status of PDMPs in each state-month were gleaned from two
separate data sources—the National Alliance for Model State Drug Laws (NAMSDL) and
the Prescription Drug Abuse Policy System (PDAPS). NAMSDL is a non-profit group that
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receives funding from the federal government to assist in the planning and
enhancement of PDMPs and also publishes resources regarding the past and present
status of PDMPs.21 PDAPS is a research tool funded by the National Institute on Drug
Abuse (NIDA) to track state laws related to prescription drug abuse. 114 The NAMSDL and
PDAPS data were both used to assess the timing of PDMP legislation enactment and
program operation. Data regarding the status of specific PDMP features, and dates that
these features were implemented, were obtained from PDAPS. These data sources are
both commonly used in longitudinal studies examining PDMPs.42,67,81,82,90,115
3.2.3 Outcome and Covariate Measures
The outcome of interest in this study was the number of hospital discharges with
a PORP diagnosis observed in each county-year-plan type set. This study chose to focus
on PORPs as we hypothesize that PDMPs have a proximal impact on this injury outcome.
PORP related discharges included discharges where a PORP diagnosis was observed in
any one of the diagnosis code fields. The CDC guide to ICD-9-CM codes related to
poisoning and pain was used to identify ICD-9-CM codes related to PORPs. The same
codes were used to define the outcome in this study as the PORP codes used in the
second chapter of this dissertation—see Table 2.1 for a list of the codes. Discharges
were not double counted if patients had more than one PORP code on a given
discharge.
Insurance status of patients observed in the HCUP discharge data was classified
according to the ‘expected primary payer’ variable associated with each discharge
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record. Each HCUP partner state collects this information in varying level of detail. To
ensure uniformity of coding across states, the expected primary payer variable in the
HCUP SID data aggregates the detailed categories reported by states into more general
groups—i.e. states may report primary expected payer as Medicaid fee-for-service or
Medicaid managed care, and HCUP will combine both of these to reflect the more
general Medicaid as the primary expected payer. The four insurance types of interest in
this study were Medicaid, Medicare, private insurance, and uninsured. In defining the
uninsured population, this study combined discharges where the primary expected
payer was listed as ‘self-pay’, ‘no charge’, or ‘other’, as these codes are commonly used
in HCUP data to identify the uninsured population.155
Demographic covariates of interest in this study included the percentage of
discharges in each county-year-plan type set corresponding to males, median age in
each county-year-plan type set, geographic region of each state, and the poverty rate
and unemployment rate in each county-year. For calculating the percentage of male
discharges in each county-year-plan type set, the total number of discharges
corresponding to male patients was divided by the total number of discharges where
gender was not missing. Gender was missing in less than 0.1% of discharges. Median age
was chosen as a covariate rather than a particular age grouping (as in the previous
study) because patients’ ages vary greatly by insurance type. Region was defined
according to US Census Bureau regions and was selected as a covariate to control for
geographic trends in PORP rates.116 Unemployment rate and poverty rate were coded as
the percentage of the population that were unemployed and the percentage of all ages
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in poverty respectively, in each county-year. These covariates were chosen as they are
generally indicative of a county’s socioeconomic status. County year unemployment rate
and poverty rate were modestly but not significantly correlated.
Clinical covariates assessed in this study included the rates of chronic and acute
pain diagnoses observed in county-year-plan type sets, and the overall discharge rate
observed in each county-year. Chronic pain was defined according to the CDC guide to
ICD-9-CM codes for poisoning and pain, and includes codes related to back pain, neck
pain, arthritis/join pain, headache/migraine, and neuropathy.95 Acute pain was defined
according to the CDC guide to ICD-9-CM codes for poisoning and pain, and includes
codes related to acute injuries. Discharges were considered to be chronic or acute painrelated if a diagnosis corresponding to either of these categories was observed in any
diagnostic field on the discharge record. Rates were calculated as the number of
discharges that were pain-related per 1,000 total discharges in each county-year-plan
type set. These covariates were chosen as they are known to be associated with opioid
prescribing. State-year-plan type rates of chronic and acute pain were also modestly but
not significantly correlated. The overall discharge rate in each county-year was
calculated as the total number of discharges observed in each county-year per 1,000
total residents in each county-year (as defined by the US Census Bureau). This covariate
was included to adjust for overall trends in ‘healthcare utilization’ within each county.
Enactment of PDMP legislation may induce changes in prescribing practices
before the programs are formally operational.42 In order to adjust for this possibility,
this study was careful to distinguish the date that PDMP legislation was enacted and the
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date that programs became formally operational. For the purposes of this study, PDMPs
were defined as being operational when they made data available to prescribers or law
enforcement officials. Dates of PDMP legislation enactment as well as dates of data
availability are reported by both NAMSDL and PDAPS, however the dates that these
groups report are at times inconsistent. To address this shortcoming, the date of PDMP
legislation enactment was conservatively defined as the earliest date reported by one of
these groups and the date that PDMPs became operational was conservatively defined
as the latest date reported by one of these groups. The PDAPS data were used when
dates were not available from NAMSDL.
Data regarding the status of specific PDMP features, and dates that these
features were implemented, were obtained from PDAPS. This study examined five
distinct features of PDMPs: 1. Whether the PDMP was operational—defined as
prescribers or law enforcement having access to the data; 2. CS Schedules monitored by
the PDMP (II-IV or II-V); 3. Frequency of data reporting from dispensers to the PDMP
central server (monthly or less, or weekly); 4. Requirement for unsolicited reporting of
patients’ CS prescription history to in-state prescribers or licensure boards; and 5.
Mandated (as defined by PDAPS) prescriber query of PDMP data prior to prescribing in
certain circumstances. Other PDMP features of interest, including mandatory
registration with the PDMP and PDMP utilization rate by prescribers, were not included
in the study due to data constraints
Each of the five PDMP variables were coded to reflect when no PDMP legislation
had been enacted, PDMP legislation was enacted but the program was not yet
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operational, and finally when the PDMP was operational with a given level of the
covariate. Each PDMP characteristic of interest, and its constituent levels are presented
in Table 3.2. Due to data constraints, not all PDMP variables in this study were coded
identically to those in the study discussed in Chapter 2. For example, the variable for
number of Schedules monitored was coded as having five levels in the Chapter 2 study
but was only coded as having four levels in the present study because there were no
state-years in the current study sample that had operational PDMPs that only
monitored Schedule II or Schedule II+III Controlled Substances. Changes to specific
PDMP features were assessed monthly and a set of time varying indicator variables
were created to describe PDMP features in each state-year. Variables were coded to
reflect the first full year that a given feature was in place for at least six months out of
that year.
3.2.4 Statistical Analysis
Generalized estimating equation (GEE) Poisson regression models were fit to
estimate the risk of PORP associated with PDMP features while adjusting for
demographic and clinical characteristics of the HCUP sample. As in the study in Chapter
2, over-dispersion was not a significant problem in these data for any of the insurance
groups investigated (the values of the deviance divided by degrees of freedom ranged
from 1.416 – 1.697 in the models investigated), so Poisson regression models were
chosen instead of negative binomial regression models. The unit of observation was the
county-year-plan type and the modeled outcome of interest was the monthly count of
PORP related discharges observed in each county-year-plan type set. Adjusted models
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were derived separately for each insurance plan type and for each PDMP feature of
interest. As in the previous study, separate models were fit for each PDMP feature to
provide greater granularity in terms of the differential impacts of each feature.
Additionally, separate models were constructed for each insurance plan type to
investigate whether there are differential associations between PDMP features and
PORP rates by type of coverage. Thus the primary results of this study are presented in
the form of twenty separate adjusted GEE models—five models for each of the four
insurance types investigated. Interaction terms could have been used rather than
stratifying the models by insurance type. However, as the primary interest in this study
is the association between PDMPs and changes in PORP rates over time, this would have
required a three-way interaction term, which can complicate model interpretation.
All twenty adjusted GEE models relied on the same assumptions and were
specified in a similar manner—the only differences being the particular PDMP feature
variable included in the model and the insurance group being investigated. Each model
included one PDMP feature variable as well as variables for time (coded as the number
of years since the study period began (i.e. 2001 = 0, 2014 = 13 etc.), geographic region,
percent of discharges for males, median age, chronic pain rate, acute pain rate,
unemployment rate, poverty rate, and discharge rate. The total count of discharges
observed in each County-year-plan type set, expressed as natural logarithms were used
as offset terms in each model to adjust for variation in the hospital utilization for any
given county-year-plan type set. Robust standard errors were calculated to adjust for
repeated measures from each state. The monthly covariance structure in each state was
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selected as a first-order autoregressive process to account for autocorrelations in the
time series for each county.
As in the previous study, all twenty adjusted GEE models also included
interaction terms between the PDMP feature of interest and time, to model the risk
difference in PORP over time in counties with and without the given PDMP feature.
These models may be interpreted as fitting multiple summary regression lines to the
data. The difference in intercepts between these lines addresses baseline differences (at
year= 0, or 2004) in mean rates of PORP in states with and without the PDMP feature of
interest. Differences in slopes—as characterized by the parameter estimate for the
interaction term—represent the different trends in PORP over time for states at
different levels of the PDMP features of interest.
The Poisson regression models were fit in SAS Enterprise Guide version 5.1 using
PROC GENMOD with the REPEATED statement to implement the GEE approach. A BY
statement was used to stratify the analysis by insurance plan type. Reference coding
scheme was used in regression parameter estimates allowing calculation of the adjusted
relative risk (aRR) for PORP associated with each variable by exponentiation of the
relevant parameter. Statistical significance was assessed as p < 0.05 for all analyses.
Figures were generated using SAS Enterprise Guide version 5.1, Tableau version 10.3
and JMP version 12.0.
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3.2.5 Sensitivity Analyses
Naloxone Access Laws
Naloxone is an FDA approved prescription medication that can be used to
reverse the effects of an acute opioid-related poisoning.122 In recent years, states have
begun to enact legislation to increase the availability of naloxone for family, friends, and
other potential bystanders of opioid-related poisonings.123 At present, all states have
enacted some sort of legislation to remove legal barriers to naloxone access. 123 Most
commonly, states have begun to permit naloxone prescribing to individuals other than
the person at risk of opioid-related poisoning, or have otherwise removed the need for
a person to see a prescriber before obtaining the medication. 123 Implementation of
these ‘naloxone access laws’ may be associated with aggregate trends in opioid-related
poisonings.90,124 As with the study in Chapter 2, this study implemented a sensitivity
analyses to control for the presence of naloxone access laws at the state level. Data on
the timing of naloxone access law implementation were gathered from PDAPS. 125 A
binary dummy variable was created to describe whether states had any type of
naloxone access laws in place for the majority of each year from 2001 – 2014. The GEE
Poisson regression models discussed in the statistical analysis section above were re-fit
including this variable in order to assess whether naloxone access laws attenuate
associations between PDMP features and trends in PORPs.
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Restricted Sample of States
Four of the states included in the main analysis of this study (NM, SD, WI and
WV) are missing data for at least one year during the study period. Missing data can bias
the results of longitudinal studies.121 With this in mind, a sensitivity analysis was
conducted removing all observations from states with limited years of data. This
method, known as listwise deletion, or complete case selection, is commonly used in
longitudinal studies with missing data.121 However, the validity of this method is
contingent on the data being ‘missing completely at random’. Data missing completely
at random implies that the data are missing because of a completely random process
that cannot be explained by any variable within or outside of the data available.121 The
four states listed above are missing data due to limited availability of the HCUP SID
county level data in certain years.156 This limited availability is purely administrative and
not related to any variables included or not included in the present analysis. Thus this
missing data arguably meets the aforementioned definition of being missing completely
at random. Results of GEE models excluding all observations from states with data
missing completely at random were compared to results from the main analysis to
qualitatively examine whether missing data from these states substantially impacted
results of the study.
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3.3 Results
3.3.1 Changes to PDMPs
The counties in the 16 state sample included in this study experienced
substantial changes in both the prevalence of PDMPs and PDMP features present from
2001 – 2014. The number of counties with operational PDMPs and the number with
specific PDMP features are displayed in Table 3.3. While 58.7% of the counties observed
in 2001 did not have PDMPs, all counties observed in 2014 had operational PDMPs in
place. Most PDMPs also began implementing robust features over this same period. In
2001, greater than three quarters of counties with operational PDMPs required
dispensers to report data monthly or less frequently, but in 2014, nearly all counties
with operational PDMPs required data reporting daily or more often. In 2001, no
counties with operational PDMPs had mandates requiring unsolicited reporting or
mandatory data querying, however in 2014, 35.1% and 25.7% respectively, of counties
with operational PDMPs had these features in place. Most counties with operational
PDMPs required all Schedules of CS to be reported throughout the study period.
3.3.2 PORP Trends
From 2001 – 2014 there were nearly 164 million discharges observed in the 16
state sample, with over 245 thousand of those discharges associated with PORPs. Over
the study period there was a statistically significant 144.4% (p < 0.0001) increase in the
mean overall PORP rate, from 88.8 to 217.0 per 100,000 total discharges. Figure 3.1
displays trends in the annual overall PORP rate from 2001 – 2004, as well as PORP rates
110

stratified by insurance type. The mean PORP rate increased significantly for all insurance
types from 2001 – 2014. The Medicare population experienced an increase of 262%, the
Medicaid population had an increase of 168% and the privately insured and uninsured
populations both saw an increase of 109% in the mean PORP rate in 2014 relative to
2001. With the exception of the Medicare population, all other insurance groups had
their highest PORP rates in 2011 before experiencing a decline in subsequent years.
There was substantial variation in the overall PORP rate observed at the state
level from 2001 – 2014. The overall PORP rates observed in each state during the study
period are displayed in Table 3.1. Several states that were only observed for limited
years from 2001 – 2014 had overall PORP rates that are markedly different from those
of other states, however, this is not unusual given the relatively limited samples from
these states (i.e. only three years observed in WI and only one year observed in WV).
Among states that were observed for the entire study period, the overall PORP rates
ranged from a high of 235.71 per 100,000 discharges in Oregon to a low of 102.4 per
100,000 discharges in Nebraska.
The overall PORP rate also varied substantially by insurance type. Table 3.4
presents the overall PORP rate and other demographic and clinical characteristics
stratified by insurance type. The uninsured population observed in this study had an
overall PORP rate over three times greater than that observed in the privately insured
HCUP population. The Medicaid population had the second highest PORP rate with
108.7 per 100,000 total discharges. Demographic and clinical characteristics of the HCUP
population also varied markedly by insurance status. The mean percent of discharges for
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male patients varied from 34.5% in the Medicaid population to nearly 54% in the
uninsured population. The mean of the median age observed in each county year also
varied as would be expected, with the Medicaid population having a mean median age
of about 24.5 and the Medicare population having a mean median age of nearly 73.
While the Medicare population had the highest rate of discharges related to chronic
pain, the uninsured population had the highest rate related to acute pain / injuries.
3.3.3 Generalized Estimating Equation Results
* Please note that PDMPs are state-level and not county-level programs,
however for the sake of brevity, ‘counties with operational PDMPs’ will be used to
describe the results throughout this section rather than the more accurate ‘counties in
states with operational PDMPs’. *
Raw parameter estimates from the GEE Poisson regression models assessing
associations between PDMP implementation status and PORP rates, stratified by
insurance plan type, are presented in Tables 3.5 A-D. Across all insurance plan types,
counties with operational PDMPs had significantly higher PORP rates relative to counties
without PDMPs at baseline. The estimated adjusted regression coefficients for time
were also positive and statistically significant for all insurance plan types. This finding is
reflected in Figure 3.6—showing that all insurance groups experienced significant
increases in PORP rates over the study period. The adjusted regression coefficient for
the interaction between the indicator for ‘PDMP operational’ and time was negative and
statistically significant for all insurance groups, suggesting that operational PDMPs
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mitigate the increases in PORP rates overt time relative to increases in counties without
PDMPs. Although all parameter estimates for the interaction between PDMP and time
were negative, the magnitude of these estimates varied markedly by PDMP status,
implying that operational PDMPs exert differential effects by insurance type. The only
other covariates that were significantly associated with PORP rates in all insurance
groups were those for geographic region, as well as rates of unemployment, chronic
pain, and acute injuries. The parameter estimates associated with these variables
generally trended in the same direction for all insurance types.
The exponentiated GEE parameter estimates from Tables 3.5 A-D are presented
in Tables 3.6 A-D. These are interpreted as changes in the adjusted relative risk (aRR) of
PORP associated with a one unit change in a given covariate while holding other
covariates constant. The main interest in these tables are the results of the time effect
variables, which indicate how the aRR of PORP changes from one year to the next in
counties with and without PDMPs. These results are also plotted in a forest plot in
Figure 3.2. In the Medicaid population (Table 3.6 A), counties without PDMPs
experienced significant increases in aRR of PORP from one year to the next (aRR: 1.023
[95% CI: 1.004 – 1.045]), while counties with operational PDMPs did not experience
significant changes in aRR of PORP over time (aRR: 0.989 [95% CI: 0.976 – 1.003]). The
uninsured population (Table 3.6 D) demonstrated similar results, with counties without
PDMPs experiencing significant increases in aRR of PORP from one year to the next
(aRR: 1.059 [95% CI: 1.037 – 1.080]), and counties with operational PDMPs not
experiencing any significant changes over time (aRR: 0.996 [95% CI: 0.981 – 1.012]. In
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the privately insured population (Table 3.6 C), counties without PDMPs as well as
counties with operational PDMPs both experienced significant increases in aRR of PORP
over time (aRR: 1.059 [95% CI: 1.043 – 1.075] and aRR: 1.019 [95% CI: 1.006 – 1.033],
respectively). Because the 95% CI’s for these two estimates do not overlap, these results
imply that in the privately insured population counties with operational PDMPs were
associated with significantly lower increases in aRR of PORP from one year to the next
relative to counties without PDMPs. Finally, in the Medicare population (Table 3.6 B),
counties without PDMPs as well as those with PDMPs experienced significant increases
in the aRR of PORP from one year to the next (aRR: 1.097 [95% CI: 1.078 – 1.117] and
aRR: 1.067 [95% CI: 1.056 – 1.079], respectively). However, since the 95% CI’s for these
estimates slightly overlap, these results suggest that in the Medicare population there
was not a significant difference in increases in aRR of PORP over time between counties
with and without PDMPs.
Results of the time effect variables in models investigating unsolicited reporting
status are presented in a forest plot in Figure 3.3. In the Medicaid population, counties
with operational PDMPs that did not require unsolicited reporting did not experience
any significant change in aRR of PORP over time (aRR: 0.992 [95% CI: 0.978 – 1.005]),
while counties with PDMPs that required unsolicited reporting experienced a protective
effect on changes in the aRR of PORP over time (aRR: 0.967 [95% CI: 0.948 – 0.985]).
Similar results were observed in the uninsured population, however the magnitude of
the protective effect in counties with proactive reporting was slightly less than that
observed in the Medicaid population (aRR: 0.981 [95% CI: 0.962 – 0.9996]). Meanwhile
114

in the privately insured population, counties with operational PDMPs that did not have
unsolicited reporting requirements experienced significant increases in aRR of PORP
over time and counties with PDMPs that did require unsolicited reporting experienced
significant decreases in aRR from one year to the next. Finally, in the Medicare
population, counties with operational PDMPs with and without unsolicited reporting
requirements both experienced significant increases in aRR over time, but those that
required unsolicited reporting experienced increases that were significantly less than
increases in counties without unsolicited reporting.
The forest plot in figure 3.4 presents the results of the time effect variables in
models investigating the number of Controlled Substance Schedules monitored. In the
Medicaid population counties with PDMPs that monitored Schedules II-IV were
associated with a protective effect on changes in aRR of PORP over time while those
monitoring all Schedules were not associated with any significant change over time.
Similarly, in the privately insured population counties that monitored Schedules II-IV
were not associated with any changes in aRR of PORP over time while those monitoring
all Schedules were associated with significant increases in aRR over time. Conversely, in
the uninsured population, counties that monitored all Schedules were associated with
no change in aRR over time while those only monitoring Schedules II-IV were associated
significant increases over time. In the Medicare population there was very little
difference in changes in aRR of PORP over time in counties that monitored all Schedules
vs. Schedules II-IV.
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Results of the time effect variables from GEE models investigating data reporting
frequency are presented in a forest plot in Figure 3.5 and generally indicate that PDMPs
requiring pharmacies to report data weekly or more frequently are associated with
protective effects on increases in aRR of PORP over time relative to PDMPs requiring
less frequent data reporting. In the Medicaid and uninsured population, counties with
weekly data reporting experienced decreases in aRR of PORP over time while counties
with operational PDMPs requiring less frequent reporting experienced no significant
change over time or significant increases over time respectively. In the privately insured
population counties with operational PDMPs that required weekly data reporting did
not experience any significant change in aRR of PORP over time while states with
operational PDMPs requiring less frequent reporting experienced significant increases.
Finally, in the Medicare population, counties with PDMPs that required weekly data
reporting were associated with significant increases in aRR of PORP over time, but these
increases were significantly less than the increases in aRR in counties without PDMPs
and those with operational PDMPs that required less frequent reporting.
The forest plot in figure 3.6 presents results of the time effect variables from
models assessing whether PDMPs require prescribers to query the PDMP data in certain
situations. In the Medicare and privately insured populations counties with operational
PDMPs that required some mandatory querying did not experience any significant
changes in aRR of PORP over time while counties with operational PDMPs that did not
require mandatory querying experienced significant increases in aRR of PORP over time.
In the Medicaid population, counties with operational PDMPs that did and did not
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require mandatory querying were not associated with significant changes in aRR of
PORP over time. In the uninsured population, counties with PDMPs that required
mandatory querying were associated with significant decreases in aRR of PORP over
time while counties with operational PDMPs that lacked this provision were not
associated with significant changes in aRR over time.
3.3.4 Sensitivity Analyses
Naloxone Access Laws
The number of states in the study sample with naloxone access laws in place
increased substantially during the study period, from 1 state in 2001 to 25 states in
2014. Overall, there were 112 state-years with naloxone access laws in place from 20012014 included in the study population. Sample Results of GEE models that were re-fit
including the naloxone access law indicator variable are presented in Tables 3.7A – 3.7D.
In the Medicaid and privately insured populations (Tables 3.7A and 3.7C, respectively),
naloxone access laws were associated with greater PORP rates, however these
associations were not statistically significant in any of the models investigated. P-values
associated with the naloxone access law variable ranged from 0.103 – 0.283 in the
Medicaid GEE models, and ranged from 0.286 – 0.747 in the privately insured GEE
models.
In the Medicare population, naloxone access laws were associated with
significantly lower PORP rates at the state-year level in all models investigated.
Parameter estimates from one of these models are presented in Table 3.7B. Although
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the naloxone access variable was statistically significant, it generally did not impact
observed associations between PDMP features and trends PORP rates. For example, in
the model presented in Table 3.7B, states both with and without operational PDMPs
experienced significant increases in PORP rates from one year to the next, and the
confidence intervals for these estimates overlap substantially. These results are nearly
identical to the results presented in the main analysis, where naloxone access laws were
not included.
Finally, in the uninsured population, naloxone access laws were associated with
lower PORP rates, but these associations generally were not statistically significant. An
example of these results is presented in Table 3.7D. Naloxone access laws were only
significantly associated with PORP rates in the uninsured population in the GEE model
investigating data reporting frequency to PDMP servers. However, once again, it was
observed that including this variable in the model only resulted in negligible changes to
the parameter estimate for the interaction between the PDMP feature variable and the
time indicator variable.
Restricted Sample of States
Results of GEE models excluding observations from states with missing data are
presented in Figures 3.7 – 3.11. Generally speaking, removing these four states from the
analysis had few consequential impacts on the primary results of interest. Figure 3.7
presents a forest plot displaying changes in aRR of PORP from one year to the next in
states with operational PDMPs. Comparing Figure 3.7 with Figure 3.2, it can be seen that
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the magnitude of the time effects in the sensitivity analysis are slightly different from
those in the main analysis, but the statistical significance of these time effects remains
the same in all insurance types investigated. For example, in both the main analysis and
the sensitivity analysis, it was seen that in the uninsured population, states with
operational PDMPs did not experience significant changes in the PORP rate from one
year to the next, while states without PMPDs experienced significant increases in PORP
rates over time. Similarly, in both analyses, it was seen that in the privately insured
population, states with operational PDMPs were associated with significantly lower
increases in PORP rates over time relative to states without PDMPs in place. These same
types of similarities between the sensitivity analysis and main analysis were also
observed in all models investigating unsolicited reporting requirements, as well as
models examining the number of CS Schedules monitored by the PDMP.
Although most of the results of the sensitivity analysis were very similar to those
observed in the main analysis, several notable differences were observed. For example,
in models investigating mandatory querying requirements in the main analysis, the
Medicaid population in states with these requirements in place did not experience any
significant changes in PORP rates over time, and the uninsured population in states with
these requirements experienced significant decreases in PORP rates over time (Figure
3.5). However, in the sensitivity analyses examining this feature, the Medicaid
population experienced significant increases in PORP rates over time while the
uninsured population did not experience any significant changes over time (Figure 3.10).
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A notable difference between the main analysis and sensitivity analysis was also
observed in models investigating how often dispensers are required to report data to
the PDMP server. In the main analysis, the privately insured population in states with
weekly data reporting did not experience any statistically significant change in PORP
rates over time. However, in the sensitivity analysis, this population experienced a
significant decrease in PORP rates from one year to the next (Figure 3.11). For all other
populations, the statistical significance of the time effects remained the same in the
sensitivity analysis.
3.4 Discussion
From 2001 – 2014, the PORP rate observed in hospital discharge data in this 16
state sample increased significantly across all insurance types. Though the uninsured
population had the highest mean PORP rate throughout the study period, the greatest
relative increase from 2001 – 2014 occurred in the Medicare population. The overall
trend observed in this study is consistent with the trend reported in a previous analysis
of HCUP data.97
This study found that across all insurance types, counties with operational
PDMPs were associated with significantly higher mean rates of PORP at baseline relative
to counties without PDMPs. Once implemented though, PDMPs generally exerted a
protective effect on increases in the aRR of PORP over time relative to counties that did
not have programs in place. Furthermore, counties with operational PDMPs that had
more robust features such as requiring more frequent data reporting from pharmacies

120

or requiring unsolicited reporting to prescribers or boards of licensure experienced
stronger protective effects on increasing rates of PORP over time relative to counties
with operational programs that lacked these features. In general these results parallel
those observed in the previous study utilizing Truven data. However, the most
significant finding of the present analysis is that differential associations between PDMP
features and trends in PORP rates do exist depending on type of insurance coverage.
Results of this study indicate that PDMPs exert particularly strong effects on the
Medicaid and uninsured populations. These were the only two groups where counties
with operational PDMPs did not experience significant changes in aRR of PORP over
time, while counties without PDMPs experienced significant increases over time. The
Medicaid and uninsured populations were also particularly impacted by more frequent
data reporting. Again, these were the only two groups where counties with operational
PDMPs that required dispensers to report PDMP data weekly or more frequently
actually experienced decreases in the aRR of PORP over time. In contrast, counties with
operational PDMPs that required less frequent data reporting experienced either no
change or significant increases in aRR of PORP over time in the Medicaid and uninsured
populations. Finally, the uninsured population was the only group to experience
decreasing RR of PORP over time in counties with operational PDMPs that required
prescribers to query the PDMP data in certain situations.
The results of models investigating the privately insured population in this study
closely resembled the results observed in the study utilizing Truven data. Once again we
see that counties with operational PDMPs experienced significant increases in the aRR
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of PORP over time, however these increases were significantly lower than the increases
observed in counties without PDMPs. Similarly, we again see that counties with
operational PDMPs that require weekly data reporting, as well as those that require
prescribers to query the PDMP data did not experience significant changes in aRR of
PORP over time while counties with PDMPs that lacked these features experienced
significant increases over time. The only marginally different result observed in the
HCUP population was that counties with unsolicited reporting requirements
experienced significant decreases in aRR over time, while in the Truven population this
feature was not associated with any significant change over time.
While PDMPs appeared to exert significant effects on the Medicaid, uninsured,
and privately insured HCUP population, the results of this study suggest that they had
less association with PORP trends in the Medicare population. The Medicare population
was the only group where counties with operational PDMPs did not experience
significantly different changes in aRR of PORP over time relative to counties without
PDMPs. However, in counties with operational PDMPs that required unsolicited
reporting, or weekly data reporting, the increases in aRR of PORP over time were
significantly lower than the increases observed in counties without PDMPs.
There are several potential reasons why PDMP implementation in general was
not seen to be associated with reductions in PORP rates in the Medicare population. For
one, prescribing in this population is potentially more likely to be related to the
treatment of chronic pain and end of life care than in other populations. This is
supported by the finding in this study that the Medicare population had a mean rate of
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chronic pain related discharges that was nearly twice as high as any other group. In this
sense, ‘overprescribing’ in patients experiencing long-term chronic pain or end of life
care may warrant less intervention from actors utilizing the PDMP, and, as such, PDMP
implementation is less associated with trends in PORP rates in this population. Second, a
primary goal of PDMPs is to reduce the diversion of CS by making doctor shopping
easier to detect. It is plausible that PDMP implementation has less of an impact on PORP
rates Medicare population relative to other groups because this population is engaged
in less diversion and doctor shopping.
Doctor shopping and diversion may also explain the stronger impact of PDMPs
on the Medicaid and uninsured population relative to the Medicare and privately
insured populations. Presumably, if PDMPs are effective at reducing doctor shopping,
then they will have a greater impact on the populations that engage in doctor shopping
at a higher rate. While it is difficult to precisely estimate the number of individuals
engaging in doctor shopping, some reports suggest that the Medicaid population
engages in doctor shopping a much higher rate than the Medicare population. A 2017
report from the Office of the Inspector General found that about 22,000 Medicare
beneficiaries nationwide appeared to be doctor shopping for opioids in 2015. 147 In
contrast, a 2009 report from the Government Accountability Office found that more
than 65,000 Medicaid beneficiaries in a five state sample engaged in doctor shopping
during fiscal years 2006 and 2007. 148 Though the GAO report is outdated and doesn’t
differentiate between opioids and other CS, these results still imply that doctor
shopping for opioids is likely to be substantially more common in the Medicaid
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population as a whole. It is even more difficult to estimate the prevalence of doctor
shopping in the uninsured population as few standardized data sources exist to monitor
their healthcare utilization. However, in his book Dreamland, journalist Sam Quinones
anecdotally reports that doctor shopping is a common practice among uninsured
individuals seeking prescription opioids.8
The main findings of this study still held upon completion of two robust
sensitivity analyses. In the first sensitivity analysis, GEE models were re-fit including an
indicator variable for the presence of naloxone access laws at the state level. Naloxone
access laws were observed to be significantly associated with PORP rates in both the
Medicare and uninsured populations. However, including this variable in the adjusted
GEE models did not result in consequential changes to the interaction terms capturing
associations between PDMP features and trends in PORP rates over time—which were
of primary interest in this study. As in the previous study, naloxone access laws were not
seen to be significantly associated with PORP rates in the privately insured population.
In the second sensitivity analysis, GEE models were re-fit excluding observations
from states with missing data. There were several notable differences observed in the
results of this sensitivity analysis relative to the results observed in the main analysis of
this study. Despite these differences though, the primary implications of the study
findings were generally consistent in both the sensitivity analysis and the main analysis.
Finally, this second sensitivity analysis was arguably unnecessary as the missing data in
the main analysis was ostensibly missing completely at random.
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Although every state except for Missouri currently has an operational PDMP, the
results of this study are still valuable to policy makers in several ways. These results
indicate that PDMPs have been more successful at mitigating trends in the opioid
epidemic in the Medicaid, uninsured, and privately insured populations than in the
Medicare population. On one hand this is good news, as the uninsured and Medicaid
populations had the highest overall rates of PORP related hospital discharges from 2001
– 2014. But on the other hand, these results also imply that more needs to be done to
address increasing PORP rates in the Medicare population—which saw the greatest
relative increase in PORP rates from 2001 – 2014. Importantly, the results of this study
imply that certain robust PDMP features may help mitigate increases in the risk of PORP
over time in the Medicare population.
This study addressed several important gaps in the PDMP literature. Most
notably, this study is the first to our knowledge to investigate differential associations
between PDMP implementation and trends in PORP risk over time in populations with
different types of insurance coverage. Prior research examining PDMPs has found mixed
results in assessing their impact on trends in opioid-related morbidity and mortality.
This study found that PDMPs exert differential effects on populations with different
types of insurance coverage. Much of the previous research examining PDMPs relies on
nationwide mortality data that does not capture insurance status. As such, this research
has not been able to account for differential associations between PDMP
implementation and trends in PORPs in populations with different types of insurance
coverage—potentially explaining the lack of conclusive findings. For example, if the
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Medicare population suffers from opioid-related mortality at a substantially higher rate
than the uninsured or Medicaid population, it could mask the effect of PDMPs in the
latter groups and indicate that PDMPs are not significantly associated with trends in
opioid-related mortality. At the very least, this research would show a diminished
impact of PDMPs on the overall population. The current study stratified results by
insurance status to provide greater granularity in terms of differential impacts of
insurance type on associations between PDMP implementation and trends in PORP.
Additionally, this study reinforced the findings in the previous chapter that
specific robust features of PDMPs impart protective effects on increasing rates of PORP
over time. Previous studies that have found that PDMPs are not effective in addressing
the opioid epidemic have often failed to take the heterogeneity of PDMP features into
account. As in the study presented in chapter two of this dissertation, the results of this
study highlight the importance of PDMPs sending unsolicited reports to prescribers or
licensure boards and requiring pharmacies to report PDMP data on a weekly basis.
These features were seen to be associated with protective effects on trends in PORP
rates over time among populations with different insurance types while adjusting for
demographic and clinical characteristics of the populations.
3.5 Limitations
This study suffered from several limitations relating both to the data sources and
study design utilized. Perhaps most notably, this study relied on the same ICD-9-CM
codes to identify PORPs as were used in Chapter 2, and thus is subject to the same
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limitations associated with the weak sensitivity of these codes.139 As in Chapter 2
though, the poor sensitivity and high specificity of these codes imply that the
magnitudes of the aRR estimates found in this study are likely underestimated relative
to their true values.140 Once again though, even though the magnitudes of these
estimates are biased, the estimates are still valuable to compare the relative impacts of
different PDMP features. Most importantly, this study’s finding that differential
associations between PDMP features and trends in PORP rates exist based on insurance
type would still hold even if the actual magnitudes of the parameter estimates are
systematically underestimated. This will hold true unless there is differential outcome
misclassification by insurance status, which is possible but unlikely.
HCUP SID data used in this study also suffers from several limitations specific to
this dataset. For example, while data on the racial makeup of HCUP hospital discharges
is available, it is often not coded, so was not used in this study. Further, there are known
weaknesses associated with using the expected primary payer variable to define
insurance status. As the variable name suggests, hospital administrators code this
variable based on who they ‘expect’ to reimburse the hospital for the patient’s stay, and
does not always reflect the patient’s true insurance status.155 The codes used to identify
uninsured patients also vary from state to state and may include patients whose care is
paid for by state specific charity groups. Whether or not these patients should be
classified as truly ‘uninsured’ is up for debate. The primary expected payer variable also
does not differentiate patients who are dually eligible for Medicare and Medicaid
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benefits, and this population may be markedly different from the general Medicare and
Medicaid populations.
The HCUP data used in this study also only includes a limited sample of 16 states.
These 16 states were selected based on availability of data pre and post implementation
of the PDMPs in each of these states. The limited state sample is also in part due to
funding constraints from the grant paying for the data. Several of the PDMP features of
interest were parameterized differently in this study than they were in the study in
Chapter 2 due to the limited sample size. For example, the variable coding the number
of Controlled Substance Schedules monitored was coded differently in the present study
because the limited study sample did not include any state-years with operational
PDMPs that only monitored Schedule II or II-III drugs. The limited number of state-years
in the current study also hampered models investigating the impact of mandatory
querying. The parameter estimates associated with this variable, and this variables
interaction with time, had unusually large standard errors because there were very few
county-years in the present study where this feature was in place.
Finally, as in the previous study, the ‘natural experiment’ design utilized in this
study is only capable of demonstrating associations and cannot be used to make
inferences about causality. Once again this is a particularly important point considering
that additional federal and state-level interventions intended to mitigate the opioid
epidemic were implemented at various points throughout the study time period. The
present study design is not able to disentangle the effects of these interventions form
the impact of PDMPs. However, even if the magnitude of the parameter estimates
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observed in this study are biased due to additional interventions that weren’t adjusted
for, they are still valuable in terms of assessing differential associations between PDMP
features and PORP rates in populations with different types of insurance coverage.
Implementation of state specific interventions may confound the impact of PDMPs in
those states, but presumably these interventions would impact people similarly
regardless of insurance status. If this assumption holds then the results of this study are
still valid in terms of the finding that PDMP implementation exerts differential effects
based on insurance type.
3.6 Conclusion
The 16 states included in this study sample experienced major changes to their
PDMPs from 2001 – 2014. This study was the first to examine trends in prescription
opioid-related morbidity in populations with different types of insurance. Over the
fourteen year study period the privately insured, Medicare, Medicaid, and uninsured
populations observed in the study sample all experienced significant increases in PORP
rates. The uninsured and Medicaid population had the highest overall PORP rates, but
the Medicare population experienced the greatest relative increase in PORP rates over
the study time period. This study was also the first to investigate differential
associations between PDMP features and trends in PORPs in populations with different
types of insurance coverage. Results of this study indicate that PDMPs have had a
greater impact on the Medicaid and uninsured populations relative to the Medicare
population. These results suggest that more needs to be done to address increasing
PORP rates in the Medicare population. Findings from the privately insured population
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in this study generally validate the findings in the previous chapter. Future research is
necessary to examine whether differential associations also exist between PDMP
features and trends in illicit opioid-related poisonings in populations with different types
of insurance.
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Table 3.1: Characteristics of states included in the HCUP SID sample
State

Time
Period

Total
Counties

County
Years

Total
Discharges

AZ

PORP
Discharges

Total
PORP
Rate
192.70

Mean
PORP
Rate
145.35

2001 15
210
10,856,641
20,921
2014
CO
2001 64
896
7,093,062
13,906
196.05 217.45
2014
FL
2001 67
938
38,419,719
75,482
196.47 273.53
2014
IA
2001 99
1386
4,820,907
5,657
117.34 143.15
2014
KY
2001 120
1680
9,110,030
17,373
190.70 246.59
2014
MI
2001 83
1162
18,519,932
32,549
175.75 296.91
2014
NC
2001 100
1400
16,213,054
27,677
170.71 196.55
2014
NJ
2001 21
294
16,753,795
17,672
105.48 117.13
2014
NM 2008 33
231
1,578,189
4,823
305.60 273.64
2014
NY
2001 62
868
36,656,825
37,541
102.41 157.46
2014
OR
2001 36
504
5,319,184
12,538
235.71 260.29
2014
SD
2007 66
528
768,899
1,092
142.02 138.65
2014
VT
2001 14
196
689,341
1,109
160.88 237.47
2014
WA 2001 39
546
8,948,500
18,337
204.92 245.71
2014
WI
2012 72
216
1,871,023
4,411
235.75 219.01
2014
WV 2001 55
55
261,342
241
92.22
95.37
2001
Acronyms: HCUP- Healthcare cost and utilization project; SID- State inpatient databases;
PORP- prescription opioid-related poisonings; States use standard postal abbreviations
**Rates expressed per 100,000 discharges**
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Table 3.2: Coding scheme for PDMP variables of interest
Variable
Status of the PDMP

Levels
0= No PDMP
1= PDMP legislation enacted only
2= PDMP operational
Is the PDMP required to send proactive
0= No PDMP
reports to any entities?
1= PDMP legislation enacted only
2= No
3= Yes
How often are pharmacies required to
0= No PDMP
upload data to the PDMP?
1= PDMP legislation enacted only
2= Monthly or less often
3= Weekly or more often
What Schedules is the PDMP required to 0= No PDMP
monitor?
1= PDMP legislation enacted only
2= II – IV
3= II – V
Are prescribers required to query the
0= No PDMP
PDMP data in certain situations?
1= PDMP legislation enacted only
2= No
3= Yes
Acronyms: PDMP- prescription drug monitoring program
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Figure 3.1: Annual PORP rate per 100,000 Discharges by insurance type 2001 – 2014

PORP Rate per 100,000 Discharges by Insurance Type
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Acronyms: PORP- prescription opioid-related poisoning
Table 3.4: Characteristics of the HCUP sample stratified by insurance type
Total
Observations
Discharges

Medicaid
11,101

Medicare
11,110

Private
11,110

Uninsured
11,104

32,447,345

62,743,302

54,569,968

13,999,539

PORP Count

58,631

81,543

59,338

45,793

Overall PORP
rate

180.70

129.96

108.74

327.10

Mean PORP
rate
Mean percent
male
Mean of
median age
Mean CP rate

192.43

125.63

113.85

362.56

34.54

44.74

41.01

53.99

24.47

72.89

42.22

41.06

117.18

365.46

189.59

193.41

Mean AP rate
76.87
147.25
114.19
187.57
Acronyms: HCUP: Healthcare Cost and Utilization Project; PORP- prescription opioidrelated poisoning; CP- chronic pain; AP- Acute pain
**Rates expressed per 100,000 discharges**
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Table 3.5A: GEE parameter estimates from model investigating PORPs in the Medicaid
population
Variable

GEE Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

0.2337
0.3854

0.3812
0.0036

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

0.0722
0.2303

Ref.
0.0824
-0.0893
0.0791
0.0752

Time Effect
Year
PDMP Enacted*year
PDMP Operational*year

0.0239
-0.0088
-0.0346

0.0104
0.0104
0.0087

0.0036
-0.0292
-0.0517

0.0443
0.0116
-0.0175

0.0211
0.3979
<.0001

-0.1377
-0.3361
-0.2601

Ref.
0.0510
-0.2377
0.0741
-0.4813
0.0765
-0.4101

-0.0377
-0.1908
-0.1101

0.0070
<.0001
0.0007

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
0.0048
0.0072
-0.0093
0.0188 0.5041
Median Age
-0.0051
0.0039
-0.0127
0.0025 0.1901
Chronic Pain Rate
0.0074
0.0008
0.0059
0.0089 <.0001
Acute Pain Rate
0.0015
0.0006
0.0003
0.0027 0.0182
Unemployment Rate
0.0266
0.0057
0.0154
0.0378 <.0001
Poverty Rate
-0.0203
0.0056
-0.0313
-0.0093 0.0003
Discharge Rate
0.0001
0.0006
-0.0011
0.0013 0.8537
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating
equation; CI- confidence interval; PDMP- prescription drug monitoring program;
**Rates expressed per 100,000 discharges**
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Table 3.5B: GEE parameter estimates from model investigating PORPs in the Medicare
population
Variable

GEE Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

0.2409
0.2652

0.0377
0.0044

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

0.1240
0.1571

Ref.
0.0597
0.0071
0.0552
0.0490

Time Effect
Year
PDMP Enacted*year
PDMP Operational*year

0.0928
-0.0185
-0.0277

0.0089
0.0072
0.0069

0.0752
-0.0326
-0.0412

0.1103
-0.0044
-0.0142

<.0001
0.0100
<.0001

-0.4723
-0.6984
-0.3120

Ref.
0.0467
-0.5638
0.0517
-0.7998
0.0591
-0.4278

-0.3808
-0.5970
-0.1961

<.0001
<.0001
<.0001

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
-0.0152
0.0053
-0.0256
-0.0049 0.0039
Median Age
-0.0210
0.0057
-0.0322
-0.0097 0.0002
Chronic Pain Rate
0.0015
0.0004
0.0008
0.0022 <.0001
Acute Pain Rate
0.0014
0.0004
0.0006
0.0023 0.0010
Unemployment Rate
0.0176
0.0049
0.0080
0.0272 0.0003
Poverty Rate
-0.0021
0.0042
-0.0103
0.0062 0.6251
Discharge Rate
-0.0001
0.0004
-0.0009
0.0007 0.7410
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating
equation; CI- confidence interval; PDMP- prescription drug monitoring program;
**Rates expressed per 100,000 discharges**
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Table 3.5C: GEE parameter estimates from model investigating PORPs in the privately
insured population
Variable

GEE Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

0.1738
0.2336

0.2945
0.0306

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

0.0606
0.1225

Ref.
0.0578
-0.0527
0.0567
0.0114

Time Effect
Year
PDMP Enacted*year
PDMP Operational*year

0.0569
-0.0228
-0.0377

0.0077
0.0070
0.0062

0.0418
-0.0365
-0.0499

0.0719
-0.0090
-0.0255

<.0001
0.0012
<.0001

-0.2097
-0.3777
-0.1608

Ref.
0.0422
-0.2924
0.0584
-0.4923
0.0449
-0.2488

-0.1270
-0.2632
-0.0727

<.0001
<.0001
0.0003

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
0.0023
0.0057
-0.0088
0.0134 0.6803
Median Age
0.0038
0.0023
-0.0007
0.0083 0.0965
Chronic Pain Rate
0.0036
0.0007
0.0023
0.0050 <.0001
Acute Pain Rate
0.0020
0.0004
0.0012
0.0028 <.0001
Unemployment Rate
0.0188
0.0040
0.0109
0.0267 <.0001
Poverty Rate
-0.0149
0.0045
-0.0237
-0.0061 0.0010
Discharge Rate
0.0004
0.0006
-0.0007
0.0016 0.4408
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating
equation; CI- confidence interval; PDMP- prescription drug monitoring program;
**Rates expressed per 100,000 discharges**
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Table 3.5D: GEE parameter estimates from model investigating PORPs in the
uninsured population
Variable

GEE Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

0.2209
0.4109

0.3766
0.0004

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

0.0687
0.2645

Ref.
0.0777
-0.0836
0.0747
0.1181

Time Effect
Year
PDMP Enacted*year
PDMP Operational*year

0.0564
-0.0221
-0.0600

0.0104
0.0090
0.0084

0.0361
-0.0398
-0.0765

0.0768
-0.0045
-0.0435

<.0001
0.0139
<.0001

0.1039
-0.2632
0.4199

Ref.
0.0543
-0.0025
0.0740
-0.4083
0.0671
0.2885

0.2103
-0.1182
0.5513

0.0557
0.0004
<.0001

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
0.0145
0.0027
0.0093
0.0198 <.0001
Median Age
-0.0018
0.0038
-0.0091
0.0056 0.6394
Chronic Pain Rate
0.0039
0.0007
0.0025
0.0054 <.0001
Acute Pain Rate
0.0025
0.0004
0.0018
0.0032 <.0001
Unemployment Rate
0.0364
0.0054
0.0259
0.0469 <.0001
Poverty Rate
-0.0257
0.0061
-0.0377
-0.0137 <.0001
Discharge Rate
-0.0020
0.0014
-0.0047
0.0006 0.1344
Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating
equation; CI- confidence interval; PDMP- prescription drug monitoring program;
**Rates expressed per 100,000 discharges**
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Table 3.6A: Adjusted relative risk of PORP in the Medicaid population
Variable

Adjusted Relative
Risk

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

1.0748
1.2590

Ref.
0.9145
1.0782

1.2632
1.4702

0.3812
0.0036

Time Effect
Year
PDMP Enacted*year
PDMP Operational*year

1.0242
1.0153
0.9894

1.0036
0.9935
0.9756

1.0452
1.0374
1.0033

0.0211
0.1698
0.1346

0.8714
0.7146
0.7710

Ref.
0.7884
0.6180
0.6636

0.9630
0.8263
0.8958

0.0070
<.0001
0.0007

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
1.0048
0.9908
1.0190
0.5041
Median Age
0.9949
0.9874
1.0025
0.1901
Chronic Pain Rate
1.0075
1.0060
1.0090
<.0001
Acute Pain Rate
1.0015
1.0003
1.0027
0.0182
Unemployment Rate
1.0270
1.0155
1.0385
<.0001
Poverty Rate
0.9799
0.9692
0.9907
0.0003
Discharge Rate
1.0001
0.9989
1.0013
0.8537
Acronyms: PORP- prescription opioid-related poisoning; CI- confidence interval; PDMPprescription drug monitoring program;
**Rates expressed per 100,000 discharges**
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Table 3.6B: Adjusted relative risk of PORP in the Medicare population
Variable

Adjusted Relative
Risk

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

1.1320
1.1701

Ref.
1.0071
1.0503

1.2724
1.3037

0.0377
0.0044

Time Effect
Year
PDMP Enacted*year
PDMP Operational*year

1.0972
1.0771
1.0672

1.0781
1.0593
1.0561

1.1166
1.0951
1.0785

<.0001
<.0001
<.0001

0.6236
0.4974
0.7320

Ref.
0.5690
0.4494
0.6519

0.6833
0.5505
0.8219

<.0001
<.0001
<.0001

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
0.9849
0.9748
0.9951
0.0039
Median Age
0.9792
0.9683
0.9903
0.0002
Chronic Pain Rate
1.0015
1.0008
1.0022
<.0001
Acute Pain Rate
1.0014
1.0006
1.0023
0.0010
Unemployment Rate
1.0178
1.0080
1.0276
0.0003
Poverty Rate
0.9980
0.9898
1.0062
0.6251
Discharge Rate
0.9999
0.9991
1.0007
0.7410
Acronyms: PORP- prescription opioid-related poisoning; CI- confidence interval; PDMPprescription drug monitoring program;
**Rates expressed per 100,000 discharges**

140

Table 3.6C: Adjusted relative risk of PORP in the privately insured population
Variable

Adjusted Relative
Risk

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

1.0624
1.1303

Ref.
0.9487
1.0115

1.1898
1.2631

0.2945
0.0306

Time Effect
Year
PDMP Enacted*year
PDMP Operational*year

1.0585
1.0347
1.0193

1.0427
1.0165
1.0057

1.0746
1.0531
1.0331

<.0001
0.0002
0.0052

0.8108
0.6854
0.8515

Ref.
0.7464
0.6112
0.7797

0.8807
0.7686
0.9299

<.0001
<.0001
0.0003

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
1.0023
0.9913
1.0135
0.6803
Median Age
1.0038
0.9993
1.0083
0.0965
Chronic Pain Rate
1.0037
1.0023
1.0050
<.0001
Acute Pain Rate
1.0020
1.0012
1.0028
<.0001
Unemployment Rate
1.0189
1.0109
1.0270
<.0001
Poverty Rate
0.9852
0.9766
0.9940
0.0010
Discharge Rate
1.0004
0.9993
1.0016
0.4408
Acronyms: PORP- prescription opioid-related poisoning; CI- confidence interval; PDMPprescription drug monitoring program;
**Rates expressed per 100,000 discharges**
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Table 3.6D: Adjusted relative risk of PORP in the uninsured population
Variable

Adjusted Relative
Risk

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted
PDMP Operational

1.0711
1.3028

Ref.
0.9198
1.1253

1.2472
1.5082

0.3766
0.0004

Time Effect
Year
PDMP Enacted*year
PDMP Operational*year

1.0581
1.0349
0.9964

1.0367
1.0124
0.9814

1.0799
1.0579
1.0117

<.0001
0.0022
0.6450

1.1095
0.7686
1.5218

Ref.
0.9975
0.6648
1.3344

1.2340
0.8886
1.7355

0.0557
0.0004
<.0001

Region
West
Midwest
Northeast
South

Continuous Variables
% male population
1.0146
1.0093
1.0200
<.0001
Median Age
0.9982
0.9909
1.0056
0.6394
Chronic Pain Rate
1.0040
1.0025
1.0054
<.0001
Acute Pain Rate
1.0025
1.0018
1.0032
<.0001
Unemployment Rate
1.0371
1.0262
1.0481
<.0001
Poverty Rate
0.9746
0.9630
0.9864
<.0001
Discharge Rate
0.9980
0.9953
1.0006
0.1344
Acronyms: PORP- prescription opioid-related poisoning; CI- confidence interval; PDMPprescription drug monitoring program;
**Rates expressed per 100,000 discharges**
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Figure 3.2: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs, stratified by insurance type

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Figure 3.3: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs with unsolicited reporting requirements, stratified by
insurance type

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Figure 3.4: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs that monitor all CS Schedules, stratified by insurance
type

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Figure 3.5: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs with mandatory querying requirements, stratified by
insurance type

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Figure 3.6: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs that require weekly data reporting, stratified by
insurance type

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Table 3.7A: GEE parameter estimates from model investigating PORP rates in the
Medicaid population, controlling for naloxone access laws
Variable

GEE Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

0.0776

0.0838

-0.0866

0.2418

0.3543

PDMP Operational

0.2418

0.0816

0.0819

0.4018

0.0030

Time Effect
Year

0.0234

0.0104

0.0030

0.0439

0.0249

PDMP Enacted*year

-0.0097

0.0105

-0.0303

0.0109

0.3561

PDMP Operational*year

-0.0364

0.0088

-0.0535

-0.0192

<.0001

Ref.

Region
West
Midwest

-0.1276

0.0508

-0.2271

-0.0281

0.0120

Northeast

-0.3507

0.0694

-0.4867

-0.2147

<.0001

South

-0.2537

0.0752

-0.4011

-0.1062

0.0007

Ref.

Naloxone Access Law in Place?
No

Ref.

Yes

0.0399

0.0304

-0.0196

0.0995

0.1890

Continuous Variables
% male population

0.0044

0.0072

-0.0098

0.0186

0.5426

Median Age

-0.0049

0.0038

-0.0124

0.0026

0.2003

Chronic Pain Rate

0.0074

0.0008

0.0059

0.0089

<.0001

Acute Pain Rate

0.0015

0.0006

0.0003

0.0027

0.0150

Unemployment Rate

0.0272

0.0058

0.0158

0.0387

<.0001

Poverty Rate

-0.0203

0.0056

-0.0313

-0.0093

0.0003

Discharge Rate

0.0001

0.0006

-0.0011

0.0013

0.8814

Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating
equation; CI- confidence interval; PDMP- prescription drug monitoring program; Refreference
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Table 3.7B: GEE parameter estimates from model investigating PORP rates in the
Medicare population, controlling for naloxone access laws
Variable

GEE Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

0.1169

0.0595

0.0002

0.2336

0.0495

PDMP Operational

0.1451

0.0571

0.0332

0.2571

0.0111

Time Effect
Year

0.0936

0.0089

0.0762

0.1110

<.0001

PDMP Enacted*year

-0.0175

0.0072

-0.0316

-0.0034

0.0149

PDMP Operational*year

-0.0259

0.0070

-0.0397

-0.0121

0.0002

Ref.

Region
West
Midwest

-0.1276

0.0508

-0.2271

-0.0281

0.0120

Northeast

-0.3507

0.0694

-0.4867

-0.2147

<.0001

South

-0.2537

0.0752

-0.4011

-0.1062

0.0007

Ref.

Naloxone Access Law in Place?
No

Ref.

Yes

-0.0560

0.0232

-0.1015

-0.0106

0.0156

Continuous Variables
% male population

-0.0155

0.0053

-0.0258

-0.0052

0.0033

Median Age

-0.0214

0.0057

-0.0326

-0.0102

0.0002

Chronic Pain Rate

0.0016

0.0004

0.0009

0.0023

<.0001

Acute Pain Rate

0.0014

0.0005

0.0005

0.0023

0.0029

Unemployment Rate

0.0167

0.0049

0.0071

0.0264

0.0007

Poverty Rate

-0.0017

0.0042

-0.0100

0.0065

0.6813

Discharge Rate

-0.0002

0.0004

-0.0010

0.0006

0.6531

Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating
equation; CI- confidence interval; PDMP- prescription drug monitoring program; Refreference
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Table 3.7C: GEE parameter estimates from model investigating PORP rates in the
privately insured population, controlling for naloxone access laws
Variable

GEE Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

0.0608

0.0576

-0.0520

0.1736

0.2909

PDMP Operational

0.1248

0.0576

0.0120

0.2377

0.0301

Time Effect
Year

0.0568

0.0077

0.0417

0.0718

<.0001

PDMP Enacted*year

-0.0230

0.0070

-0.0367

-0.0093

0.0010

PDMP Operational*year

-0.0384

0.0064

-0.0509

-0.0258

<.0001

Ref.

Region
West

Ref.

Midwest

-0.2060

0.0435

-0.2913

-0.1207

<.0001

Northeast

-0.3824

0.0586

-0.4973

-0.2675

<.0001

South

-0.1585

0.0454

-0.2475

-0.0695

0.0005

Naloxone Access Law in Place?
No

Ref.

Yes

0.0161

0.0307

-0.0441

0.0764

0.5994

Continuous Variables
% male population

0.0023

0.0057

-0.0088

0.0134

0.6838

Median Age

0.0038

0.0023

-0.0007

0.0083

0.0978

Chronic Pain Rate

0.0036

0.0007

0.0023

0.0049

<.0001

Acute Pain Rate

0.0020

0.0004

0.0012

0.0028

<.0001

Unemployment Rate

0.0191

0.0041

0.0111

0.0271

<.0001

Poverty Rate

-0.0149

0.0045

-0.0238

-0.0061

0.0009

Discharge Rate

0.0004

0.0006

-0.0007

0.0016

0.4329

Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating
equation; CI- confidence interval; PDMP- prescription drug monitoring program; Refreference

150

Table 3.7D: GEE parameter estimates from model investigating PORP rates in the
uninsured population, controlling for naloxone access laws
Variable

GEE Parameter
Estimate

Standard
Error

95% CI
Lower

95% CI
Upper

P
Value

PDMP Status
No PDMP
PDMP Enacted

0.0609

0.0782

-0.0923

0.2141

0.4361

PDMP Operational

0.2534

0.0772

0.1020

0.4048

0.0010

Time Effect
Year

0.0575

0.0105

0.0369

0.0780

<.0001

PDMP Enacted*year

-0.0211

0.0091

-0.0389

-0.0034

0.0198

PDMP Operational*year

-0.0581

0.0087

-0.0753

-0.0410

<.0001

Ref.

Region
West

Ref.

Midwest

0.0872

0.0556

-0.0217

0.1962

0.1167

Northeast

-0.2459

0.0771

-0.3971

-0.0947

0.0014

South

0.4068

0.0684

0.2727

0.5410

<.0001

Naloxone Access Law in Place?
No

Ref.

Yes

-0.0740

0.0410

-0.1544

0.0064

0.0712

Continuous Variables
% male population

0.0146

0.0027

0.0093

0.0198

<.0001

Median Age

-0.0020

0.0038

-0.0093

0.0054

0.6000

Chronic Pain Rate

0.0040

0.0008

0.0025

0.0055

<.0001

Acute Pain Rate

0.0025

0.0004

0.0017

0.0032

<.0001

Unemployment Rate

0.0352

0.0055

0.0244

0.0461

<.0001

Poverty Rate

-0.0252

0.0062

-0.0373

-0.0131

<.0001

Discharge Rate

-0.0021

0.0014

-0.0048

0.0006

0.1215

Acronyms: PORP- prescription opioid-related poisoning; GEE- generalized estimating
equation; CI- confidence interval; PDMP- prescription drug monitoring program; Refreference
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Figure 3.7: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs, stratified by insurance type, excluding states with
missing data
Model

Uninsured

Private

Medicare

Medicaid
aRR [LCL - UCL]

Medicaid
No PDMP

1.0237 [ 1.0026 - 1.0453 ]

PDMP Enacted

1.023 [ 1.0016 - 1.0449 ]

PDMP Operational

0.9882 [ 0.974 - 1.0027 ]

Medicare
No PDMP

1.0982 [ 1.0789 - 1.1179 ]

PDMP Enacted

1.0793 [ 1.0606 - 1.0983 ]

PDMP Operational

1.0669 [ 1.056 - 1.078 ]

Private
No PDMP

1.0568 [ 1.0406 - 1.0733 ]

PDMP Enacted

1.0358 [ 1.0166 - 1.0553 ]

PDMP Operational

1.0191 [ 1.005 - 1.0333 ]

Uninsured
No PDMP

1.0554 [ 1.0336 - 1.0776 ]

PDMP Enacted

1.035 [ 1.0111 - 1.0595 ]

PDMP Operational

0.9944 [ 0.9791 - 1.0099 ]

0.95

1.00

1.05

1.10

1.15

aRR and 95% CI

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Figure 3.8: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs with unsolicited reporting requirements, stratified by
insurance type, excluding states with missing data
Model

Uninsured

Private

Medicare

Medicaid
aRR [LCL - UCL]

Medicaid
No PDMP

1.0241 [ 1.0033 - 1.0454 ]

PDMP Enacted

1.0235 [ 1.0027 - 1.0447 ]

No Reporting

0.9912 [ 0.9771 - 1.0055 ]

Reporting Required

0.9641 [ 0.9452 - 0.9833 ]

Medicare
No PDMP

1.0972 [ 1.0781 - 1.1167 ]

PDMP Enacted

1.0789 [ 1.0607 - 1.0974 ]

No Reporting

1.0707 [ 1.06 - 1.0815 ]

Reporting Required

1.0377 [ 1.021 - 1.0547 ]

Private
No PDMP

1.0564 [ 1.0407 - 1.0723 ]

PDMP Enacted

1.0371 [ 1.0187 - 1.0559 ]

No Reporting

1.0233 [ 1.0096 - 1.0373 ]

Reporting Required

0.9775 [ 0.9575 - 0.9979 ]

Uninsured
No PDMP

1.0561 [ 1.0344 - 1.0783 ]

PDMP Enacted

1.0359 [ 1.012 - 1.0605 ]

No Reporting

0.9981 [ 0.9823 - 1.0141 ]

Reporting Required

0.9801 [ 0.961 - 0.9994 ]

0.95

1.00

1.05

1.10

1.15

aRR and 95% CI

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Figure 3.9: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs that monitor all CS Schedules, stratified by insurance
type, excluding states with missing data
Model

Uninsured

Private

Medicare

Medicaid
aRR [LCL - UCL]

Medicaid
No PDMP

1.024 [ 1.0028 - 1.0457 ]

PDMP Enacted

1.0234 [ 1.0019 - 1.0454 ]

II - IV

0.968 [ 0.9425 - 0.9942 ]

II - V

0.989 [ 0.9746 - 1.0036 ]

Medicare
No PDMP

1.0983 [ 1.0789 - 1.1181 ]

PDMP Enacted

1.0794 [ 1.0608 - 1.0983 ]

II - IV

1.0513 [ 1.0257 - 1.0775 ]

II - V

1.0673 [ 1.0562 - 1.0785 ]

Private
No PDMP

1.0567 [ 1.0403 - 1.0733 ]

PDMP Enacted

1.0363 [ 1.0171 - 1.0558 ]

II - IV

1.0017 [ 0.9805 - 1.0233 ]

II - V

1.0192 [ 1.005 - 1.0336 ]

Uninsured
No PDMP

1.0547 [ 1.0327 - 1.0773 ]

PDMP Enacted

1.0343 [ 1.0103 - 1.059 ]

II - IV

1.0369 [ 1.0001 - 1.075 ]

II - V

0.9933 [ 0.9777 - 1.0092 ]

0.95

1.00

1.05

1.10

1.15

aRR and 95% CI

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Figure 3.10: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs with mandatory querying requirements, stratified by
insurance type, excluding states with missing data
Uninsured

Model

Private

Medicare

Medicaid

aRR [LCL - UCL]
Medicaid
No PDMP

1.0236 [ 1.0025 - 1.0451 ]

PDMP Enacted

1.0231 [ 1.0015 - 1.0451 ]

No Mandatory Queries

0.9891 [ 0.9745 - 1.0039 ]

Some Mandatory Queries

1.1915 [ 1.0318 - 1.376 ]

Medicare
No PDMP

1.0982 [ 1.0788 - 1.1179 ]

PDMP Enacted

1.0795 [ 1.0608 - 1.0986 ]

No Mandatory Queries

1.068 [ 1.0568 - 1.0794 ]

Some Mandatory Queries

1.0901 [ 0.9442 - 1.2586 ]

Private
No PDMP

1.0566 [ 1.0404 - 1.0731 ]

PDMP Enacted

1.0359 [ 1.0166 - 1.0555 ]

No Mandatory Queries

1.0204 [ 1.006 - 1.035 ]

.Some Mandatory Queries

1.1183 [ 0.9267 - 1.3495 ]

Uninsured
No PDMP

1.0555 [ 1.0337 - 1.0778 ]

PDMP Enacted

1.0359 [ 1.0118 - 1.0605 ]

No Mandatory Queries

0.997 [ 0.9812 - 1.013 ]

.Some Mandatory Querie

0.8649 [ 0.73 - 1.0247 ]

0.8

1.0

1.2

1.4

aRR and 95% CI

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval

155

Figure 3.11: Forest plot displaying change in aRR of PORP from one year to the next in
states with operational PDMPs that require weekly data reporting, stratified by
insurance type, excluding states with missing data
Uninsured

Model

Private

Medicare

Medicaid
aRR [LCL - UCL]

Medicaid
No PDMP

1.0249 [ 1.0036 - 1.0466 ]

PDMP Enacted

1.0263 [ 1.0037 - 1.0494 ]

Monthly

0.9962 [ 0.9803 - 1.0123 ]

Weekly

0.9595 [ 0.937 - 0.9825 ]

Medicare
No PDMP

1.1015 [ 1.0825 - 1.1208 ]

PDMP Enacted

1.0856 [ 1.0666 - 1.1048 ]

Monthly

1.079 [ 1.0668 - 1.0913 ]

Weekly

1.0282 [ 1.0094 - 1.0475 ]

Private
No PDMP

1.0579 [ 1.0418 - 1.0743 ]

PDMP Enacted

1.0399 [ 1.0202 - 1.06 ]

Monthly

1.0341 [ 1.0192 - 1.0492 ]

Weekly

0.9746 [ 0.9531 - 0.9966 ]

Uninsured
No PDMP

1.0592 [ 1.0372 - 1.0816 ]

PDMP Enacted

1.0397 [ 1.0148 - 1.0651 ]

Monthly

1.0204 [ 1.0038 - 1.0372 ]

Weekly

0.9327 [ 0.9077 - 0.9585 ]

0.90

0.95

1.00

1.05

1.10

1.15

aRR and 95% CI

Acronyms: aRR- adjusted relative risk; PORP- prescription opioid-related poisoning;
PDMP- prescription drug monitoring program; LCL- lower confidence limit; UCL- upper
confidence limit; CI- Confidence interval
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Chapter 4: Reflections and Recommendations
4.1 Filling in the gaps
Clarifying the role of operational PDMPs
The literature review in Chapter 1 notes that many of the previous studies
examining the impact of PDMPs on opioid-related morbidity and mortality failed to
adequately describe what they considered to be operational PDMPs. Green et al.
articulated this criticism in response to an earlier study by Paulozzi et al. Green and
colleagues argued that it was inappropriate for Paulozzi to consider PDMPs as ‘active’ or
operational when the programs had not yet made data available to authorized users.
Understandably, as data based interventions, it is difficult to conceive how these
programs could serve any of their intended goals if users were not able to access, and
subsequently act on, the data collected. The studies in this dissertation make clear that
PDMPs are only considered operational when they have made data available to
authorized users. Furthermore, several previous studies that did specify that PDMPs
were only considered operational when they had made data available to users, only
used one data source to identify dates of user access.42,90 This is problematic because
NAMSDL and PDAPS both report dates of user access, but the dates they report are at
times inconsistent. The studies in this dissertation used dates reported by both NAMSDL
and PDAPS to conservatively define PDMPs as operational only after the latest date
reported by one of these groups.
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The studies presented in this dissertation found that states with operational
PDMPs are generally associated with higher baseline PORP rates, but once implemented
these programs are associated with significantly lower increases in PORP rates over time
relative to states without PDMPs. This finding held for all groups examined except for
the Medicare population, which did not experience significant differences in trends in
PORP rates regardless of whether they lived in PDMP states. It is plausible that states
that have the worst problems with PORPs are the states that choose to implement these
programs sooner. This hypothesis is consistent with the finding that states with
operational PDMPs had higher PORP rates at the beginning of the study periods relative
to states without operational PDMPs.
Associations between PDMP features and PORPs
Despite the well-known heterogeneity of PDMPs between states, many studies
investigating the effects of PDMPs simply classify the programs as being ‘on’ or ‘off’ and
fail to account for the subtle differences in specific features of operational PDMPs. To
date, only two previous studies have investigated associations between specific features
of operational PDMPs and trends in PORP rates.42,90 Further, one of these studies only
shows that states with more PDMP features are associated with reductions in PORP
rates, and does not present results that can be used to interpret the effects of individual
PDMP features.90 The studies presented in this dissertation utilized rigorous feature
attribution methods to characterize features of PDMPs in every state in every year from
2001 – 2014. The study presented in Chapter 2 also builds on previous studies by
examining features of PDMPs in every month rather than on a yearly basis. PDMPs
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frequently integrate new features in the middle of calendar years so examining changes
monthly may better capture the immediate impact of these features. Finally, the studies
in this dissertation also developed separate statistical models for each PDMP feature of
interest, so these results provide greater granularity than those of previous studies in
terms of the relative effects of each PDMP feature on trends in PORPs and IORPs.
The studies in this dissertation found that several features of operational PDMPs
are associated with significantly lower increases in PORP risk over time relative to states
with operational PDMPs that lack these features. For example, in the privately insured
population, states with operational PDMPs that required pharmacies to submit data on
a weekly basis, and those that required prescribers to query the PDMP data in certain
situations were not associated with significant changes in PORP rates over time, while
those states with operational PDMPs that lacked these features, were associated with
significant increases in PORP rates over time. This study also found that states with
operational PDMPs with these features were associated with protective effects on
increases in PORP rates over time in the Medicaid and uninsured populations. Overall,
this study found that three of the four specific PDMP features investigated imparted
beneficial effects on all populations studied. Namely, operational PDMPs that required
unsolicited reporting, mandated prescribers query the PDMP data in certain situations,
and those that required pharmacies to submit data more frequently were associated
with either protective effects on the trends in PORP rates over time, or at worst, were
associated with lower increases in PORP rates over time relative to states with
operational PDMPs that lacked these features. These findings both confirm and expand
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upon the findings of previous studies investing associations between PDMP features and
trends in PORP rates.
Differential associations in populations with different types of insurance
None of the previous studies investigating associations between PDMPs and
trends in PORPs have taken into account the possibility of differential associations in
populations with different types of insurance coverage. As healthcare based programs
that operate at the point-of-care, it is plausible that operational PDMPs and PDMPs with
certain features will exert differential impacts on trends in opioid-related morbidity and
mortality in different insurance beneficiary populations. However, nearly all of the
previous research examining the impact of PDMPs on fatal and nonfatal PORPs has been
conducted using data sources where the researchers cannot observe the insurance
status of individuals included in the study. The study in Chapter 3 used hospital
discharge records that included data on the expected primary payer for each hospital
stay. Thus this study was able to construct separate models for each payer type to
investigate associations between PDMP implementation and trends in PORPs. This study
also investigated whether type of insurance coverage exerts differential effects on
associations between specific PDMP features and trends in PORPs. Results of this study
both elucidated the importance of insurance status on the effects of PDMPs and
validated the results observed in the study in Chapter 2.
Importantly, the results of models investigating the privately insured population
in Chapter 3 validate the results observed in Chapter 2. Inspecting Figures 2.3 and 3.1,
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we can see that the privately insured Truven population and the privately insured HCUP
population generally experienced similar trends in PORP rates from 2004 – 2014. In both
populations the PORP rate approximately doubled from 2004 – 2011 and has since
levelled off. Models investigating associations between PDMP features and changes in
PORP rates over time also revealed similar results for these two populations. Figure 4.1
presents a side-by-side comparison of these results. Although the magnitudes of the
observed parameter estimates differ, these results are generally trending in the same
direction. For example, in both populations, states with operational PDMPs are
associated with significantly lower increases in PORP rates over time relative to states
without PDMPs. These results also held when investigating specific features of
operational PDMPs. For example, in both populations, states with operational PDMPs
that required weekly data reporting were not associated with significant changes in
PORP rates over time, while states with operational PDMPs that required monthly or
less frequent data reporting were associated with significant increases in PORP rates
over time. Given these similarities, we can see that these results are not merely a
‘function of the data’, and are likely indicative of the true associations between PMDP
implementation and trends in PORPs in the privately insured population.
Associations between PDMPs and IORPs
Few studies to date have attempted to investigate associations between PDMP
implementation and trends in illicit opioid-related morbidity. Mortality data from the
CDC suggests that increases in fatal PORPs have begun to level off in recent years while
rates of fata IORPs have increased dramatically.143 Similar trends in PORP and IORP rates
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were observed in Chapter 2 of this dissertation. Some individuals have argued that the
widespread implementation of PDMPs may in part be contributing to increases in IORPS,
however few researchers have sought to empirically test this hypothesis. The study
presented in Chapter 2 was the first study to examine differential associations between
PDMP implementation and trends in PORPs vs. IORPs. Results of the study are bolstered
by the fact that these distinct analyses were conducted using nearly identical
methodologies on the exact same population of privately insured adults. Thus the
different results from the separate analyses cannot be attributed to variations in study
design or the population observed. This study also examined whether specific features
of operational PDMPs had differential associations with trends in IORP rates.
Results of the study presented in Chapter 2 indicate that PDMPs likely are not
driving the recent increase in IORPs. In this study, states with operational PDMPs
experienced significant increases in the risk of IORP over time, but these increases were
not significantly different than those observed in states without PDMPs. In most cases,
States with specific PDMP features also did not experience significant differences in
increases in IORP risk over time relative to states without PDMPs. The exception were
states with operational PDMPs that required unsolicited reporting. States with
operational PDMPs that required unsolicited reporting experienced significantly greater
increases in IORP risk over time relative to states with operational PDMPs that did not
require unsolicited reporting, and relative to states without PDMPs. In models
examining associations between PDMP features and trends in PORPs, PDMPs that
required unsolicited reporting were associated with protective effects changes in PORP
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rates over time. Taken together these results lend some credence to the theory that
PDMPs may reduce PORPs while increasing IORPs. However, it is not immediately clear
why data reporting frequency—which was also associated with significant protective
effects on risk of PORP over time—is not also associated with increased risk of IORP over
time.
4.2 Directions for future research
The studies included in this dissertation investigated a number of widely
implemented PDMP features. However, there are several additional characteristics of
PDMPs that may also be associated with trends in PORP and IORP rates that were not
included in this study due to data constraints. Some PDMPs have begun requiring
prescribers and pharmacists to register with the PDMP system. Previous research in
Kentucky found that implementation of this feature was associated with reductions in
doctor shopping, but prior studies have not examined associations between mandatory
registration and trends in PORPs or IORPs.53 Unfortunately, at the time that the studies
in this dissertation were conducted, data on mandatory registration were not available
from PDAPS or other sources. In addition to mandatory registration, the rate at which
prescribers query the PDMP data may also be associated with trends in opioid-related
morbidity. Likewise though, aggregate data on prescriber querying rates are not readily
available. Finally, interstate data sharing between PDMPs in neighboring states has
become increasingly popular in recent years however the effect of this feature on PORPs
and IORPs has yet to be examined. Future research is necessary to understand whether
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these characteristics of PDMPs are associated with trends in prescription and illicit
opioid-related morbidity and mortality.
One of the primary limitations of the studies in this dissertation is that they fail
to account for additional state and federal interventions that may have impacted trends
in PORPs and IORPs during the study periods. State-level policy changes that may have
impacted trends in opioid-related morbidity include things like crackdowns on pill mills
in certain states, medical marijuana legislation, and Good Samaritan laws. National-level
changes may include things like the release of abuse deterrent formulations of
oxycodone, implementation of the Patient Protection and Affordable Care Act, and the
revising of opioid prescribing guidelines. Some previous research has examined how
these state and national-level interventions have effected trends in PORPs and IORPs.
However, additional research is necessary to examine the impact of these trends in the
context of changes to PDMP features over the last 20 years.
Future research is also needed to elucidate the particular mechanisms by which
PDMP features are associated with aggregate trends in rates of PORPs and IORPs, and
whether these mechanisms operate differently in populations with different types of
insurance. The studies presented here found that certain PDMP features are associated
with significant protective effects on trends in PORP rates in multiple diverse
populations, represented by different data sources. However, these results do not
immediately make clear the mechanisms underlying these associations. It may be that
PDMPs lead to reductions in PORP rates as they equip physicians with timely data on
patients’ CS use history, which will allow physicians to make more informed prescribing
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decisions. Alternatively, PDMPs may primarily act to reduce aggregate PORP rates by
allowing law enforcement, or boards of licensure, to identify patients and prescribers
that may be contributing to medication diversion. Once identified, law enforcement, or
boards of licensure, may remove these ‘bad actors’ and ultimately reduce the aggregate
risk of PORP at the state level. These different mechanisms may contribute to the
finding that PMDPs have weaker associations with PORP trends in the Medicare
population relative to populations with different types of insurance coverage. Future
research, attempting to elucidate these mechanisms, may allow for the implementation
of additional policy measures to further strengthen existing PDMPs, and to improve the
effectiveness of PDMPs at reducing PORP rates in the Medicare population.
Finally, future research is needed to explore associations between PDMP
features and trends in additional outcomes such as opioid prescribing and doctor
shopping. There has been a great deal of research examining the impact of PDMP
implementation on opioid prescribing. Many of these studies have found that PDMPs
are associated with decreases in Schedule II opioid prescribing and increases in Schedule
III opioid prescribing.157-160 However, much of this research suffers from the same
limitation as previous research examining associations between PDMPs and opioidrelated morbidity, in that many of these studies fail to account for the heterogeneity of
PDMP features between states. Future research on this topic should control for the
PDMP features observed in this dissertation to exert protective effects on trends in
PORP rates. There is also a general dearth of research examining associations between
PDMPs and doctor shopping. One study in Kentucky found that requiring prescribers to
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register with the PDMP was associated with a reduction in doctor shopping in the
Medicaid population.53 Additional research is necessary to identify whether this was an
isolated finding, and also whether additional features of PDMPs may be associated with
trends in doctor shopping in populations with other types of insurance coverage.
4.3 Policy Recommendations
Implement robust PDMP features
This findings presented in this dissertation should be used as empirical evidence
to support the adoption of several robust PDMP features. At present, 49 states and the
District of Columbia have operational statewide PDMPs in place.66 The last holdout,
Missouri, has enacted PDMP legislation and the program is operational in certain
counties. Even though almost all states now have operational PDMPs, many of these
programs lack features that this dissertation found to exert protective effects on trends
in PORP risk. As of July 1st, 2016, 45 of the 50 operational PDMPs require dispensers to
upload data to the PDMP server at least weekly. However, only 15 of those PDMPs
require dispensers to upload data daily or more frequently.66 The study in Chapter 2
found that states with daily or more frequent reporting were associated with significant
decreases in PORP risk over time. This finding suggests that more states should
implement this feature moving forward. Similarly, 11 states with operational PDMPs still
do not have unsolicited reporting requirements in place, which this study also found to
be associated with protective effects on changes in PORP rates over time in certain
populations.49 Finally, the studies in this dissertation found that states with operational
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PDMPs that require prescribers to query the PDMP data in certain situations were not
associated with significant changes in PORP risk over time, while states with operational
PDMPs that lacked this feature were associated with significant increases over time. 66
Unfortunately, estimates for this variable were generally imprecise due to the limited
sample of state-years where this feature was in place during the study periods. As of
2016, only 18 PDMPs had this feature in place.66
Implementation of robust PDMP features may not immediately lead to
reductions in PORP rates, but the findings presented in this dissertation suggest that at
worst they will exert protective effects on increases in PORP rates over time. These
studies also suggest that PDMPs are not necessarily contributing to recent increases in
rates of IORPs, as has been suggested anecdotally. Regardless of their impact on the
current opioid epidemic however, robust PDMPs will inevitably serve an important
utility to the US healthcare infrastructure moving forwards. Having a widely accessible,
real time data collection tool in place to monitor CS prescribing and dispensing, will
almost certainly help mitigate future increases in rates of prescription CS poisonings,
before these issues reach the scope of the current opioid epidemic. For example,
gabapentin has recently emerged as a medication commonly found in post-mortem
toxicology reports.161 While PDMPs largely served as reactive interventions to the opioid
epidemic, they can now serve as proactive tools to prevent a potential gabapentin
epidemic long before it begins. However, in order for PDMPs to serve the greatest utility
in preventing future prescription drug epidemics, it is vitally important that they
implement the robust features identified in this study.
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Treating demand as well as supply
Addiction is a neurobiological disease that fundamentally alters the brain’s
pleasure-reward pathways.162 PDMPs are supply-side interventions that inherently act
to reduce the amount of opioids available to a population. These programs may make it
more difficult for individuals to become addicted in the first place—i.e. by encouraging
appropriate prescribing practices or reducing the supply of medication that can be
diverted to patients who are not yet addicted—but they do little to assist patients who
are already compulsively seeking and taking drugs. Individuals addicted to prescription
opioids who are suddenly facing reduced accessibility have a cheap and readily available
substitute in the form of heroin, or illicitly manufactured fentanyl. Previous research has
found that supply side interventions intended to reduce opioid related-morbidity and
mortality may be ineffective in the presence of substitutes.163 With this framework in
mind, it is important that PMDPs attempt to innovate in order to also address the
‘demand’ side of the prescription opioid marketplace.
Presently, PDMPs offer few tools to assist patients in need of addiction
treatment. Prescribers who fastidiously check the PDMP data may find that patients are
actively engaged in doctor shopping and may thus choose not to prescribe these
patients opioids. Indeed, prior research has found that some doctors alter their
prescribing decision-making upon reviewing patients CS history via a PDMP.134,164
Unfortunately, this decision will likely serve little benefit to a patient who is already
addicted to prescription opioids. Instead, it would be more helpful if doctors in this
situation were to offer counseling or refer patients to an SUD treatment provider.
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PDMPs could be equipped to help facilitate this process by providing doctors in this
situation with sample language on how to discuss patients’ CS history, or by providing
the doctor information on SUD treatment services available in the area. Furthermore,
PDMPs could be integrated with additional data sources to help doctors identify
patients who may be suffering from SUD. West Virginia’s PDMP has begun to take this
approach as recent legislation requires all first responders and ER physicians to report
acute opioid-related poisonings to the states PDMP.165
The PDMP innovations proposed above may be both costly and years away from
implementation. In the meantime, states should work in concert with the federal
government to improve access to SUD treatment services. Kentucky and West Virginia,
two of the states hardest hit by the opioid epidemic, are already taking strides in this
direction through the implementation of Medicaid 1115 waivers that will open up new
treatment services to Medicaid recipients.166 When these waivers are implemented
managed care organizations in these states will be required to reimburse providers for
certain types of SUD treatment services related to both behavioral therapy as well as
medication assisted treatment that were previously not available to the Medicaid
populations in these states. Presumably, alleviating the financial burden of treatment
will encourage more SUD patients to seek care, and ideally will eventually lead to better
outcomes. In order for this to work though, it is important for individuals to retain
access to Medicaid coverage. Results in this dissertation showed that the uninsured
population had substantially higher PORP rates from 2001 – 2014 than any group with
public or private insurance. With this in mind, states and the federal government will
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need to provide services for these individuals as well. However the quality and financial
source of this care is up for debate. It will also be important for states and the federal
government to work to improve access to Naloxone in order to reduce opioid-related
mortality.
4.4 Conclusion
Over the last 20 years, PDMPs have been a key element in the fight against the
opioid epidemic. These programs offer an unrivaled utility to track and prevent CS
misuse and diversion, and by way of these efforts, to ultimately reduce the burden of
prescription opioid-related morbidity and mortality on the US public health
infrastructure. The results presented here demonstrate that states with operational
PDMPs experienced significantly lower increases in PORP rates from 2004 – 2014
relative to states without operational PDMPs. However, these results differed by the
insurance status of the population being studied. The studies in this dissertation also
found that specific features of operational PDMPs are associated with stronger
protective effects on changes in PORP risk over time relative to states with operational
PDMPs that lack these features. These findings have addressed several prominent
shortcomings of the existing PDMP literature. Moving forward, PDMPs should continue
to implement requirements for more frequent data reporting from pharmacies,
mandatory querying of the PDMP data, and unsolicited reporting to providers and
boards of licensure. Furthermore, additional ‘demand’ side interventions related to SUD
treatment are necessary to have the greatest impact on the US opioid epidemic.
Ultimately, PDMPs have served a demonstrated benefit in addressing the current opioid
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epidemic, and now that the ground work is in place, they will ideally help prevent future
prescription drug epidemics as well.
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